Category Archives: Healthcare & Pharma / 医药医疗

China’s Segmented Pharmaceutical Production Rules Move From Pilot to Standing Procedure

  • The National Medical Products Administration issued a consultation draft on 13 November 2026 that would convert segmented pharmaceutical production from a case-by-case pilot into a standing procedure, with comments due by 30 November 2026.
    国家药监局于 2026 年 11 月 13 日发布征求意见稿,拟把药品分段生产从”一事一议”的试点转为常规程序,反馈截止 2026 年 11 月 30 日。
  • The draft runs to six parts and twenty-three articles and rests on the revised Regulation for the Implementation of the Drug Administration Law, in force since 15 May 2026, while the biologics pilot it supersedes runs out on 31 December 2026.
    征求意见稿共六部分二十三条,上位依据是 2026 年 5 月 15 日起施行的新修订《药品管理法实施条例》;它所接替的生物制品试点将于 2026 年 12 月 31 日到期。
  • Four categories of product may be split across sites, and the fourth — an originator drug already approved in China but made abroad, with some or all steps moved onshore — is the new addition.
    可分段生产的品种共四类,其中第四类为新增:已取得境内上市许可、在境外生产、部分或全部工序转移至境内分段生产的原研药品。
  • At least one side of a sterile arrangement must hold three years of commercial sterile manufacturing experience in the same dosage form, and only two of the four relaxations listed in the 2025 No. 134 announcement are carried over.
    无菌药品安排中,委托方与受托方至少一方须具备同剂型三年以上商业化生产经验;2025 年第 134 号公告所列四项放宽情形中,仅两项被沿用。
  • Cross-border commissioning opens in one direction only: a foreign Marketing Authorization Holder may move steps into China, while a domestic holder may not in principle commission manufacturing abroad, save for the fourth category.
    跨境委托只单向开放:境外持有人可以把工序放到境内,境内持有人原则上不得委托境外生产,第四类原研药除外。
  • Antibody-Drug Conjugate intermediates that are not managed as drugs or as active pharmaceutical ingredients are excused from holding a drug manufacturing licence, but still face GMP compliance, inspection and a licence annotation.
    抗体偶联药物中不按药品或原料药管理的中间产品,可免于办理药品生产许可证,但仍须符合 GMP、接受检查并在许可证上载明。
  • The obligations land squarely on the holder: two or more technical staff stationed on site for each product in production, one full-system GMP audit of every site each year, and a quality risk review chaired by the legal representative or the enterprise head.
    义务落在持有人身上:每个在产品种驻厂技术人员不少于两名,每年对全部生产场地至少开展一次全体系 GMP 审核,并由法定代表人或企业负责人主持质量风险会商。

China’s Segmented Pharmaceutical Production Rules Move From Pilot to Standing Procedure | 中国药品分段生产:从试点走向常规程序

Why this matters now

On 13 November 2026 the general office of the National Medical Products Administration published a consultation draft titled Announcement on Matters Concerning Segmented Production of Entrusted Drugs. Comments close on 30 November 2026 and go to a dedicated mailbox. The text is a draft. Nothing in it binds anyone until the final version is issued, and the final version may differ in wording, in scope, and in the transitional arrangements it attaches to products already in the pipeline.

What makes the draft worth reading now rather than in December is the calendar behind it. The segmented production pilot for biologics opened in October 2024 and closes on 31 December 2026. The revised Regulation for the Implementation of the Drug Administration Law has been in force since 15 May 2026. Between those two dates sits a gap: the Regulation provides the legal basis for splitting manufacturing across sites, but the operational route has been a pilot run on a case-by-case basis, with entry negotiated rather than published. The draft fills that gap by writing the criteria down.

Segmented production, in plain terms, means one product whose manufacturing steps are carried out at more than one site, sometimes by more than one legal entity, under a single quality assurance system that the marketing authorization holder owns. It is not outsourcing in the ordinary sense. The holder does not hand over responsibility along with the process; it keeps the responsibility and distributes the work. That distinction drives almost every clause in the draft.

For a foreign group, three features of the draft stand out. The first is the fourth eligible category, which for the first time gives an approved originator product made overseas a route to move some or all of its steps into China without re-registering as a new drug. The second is the direction of the cross-border rule: the door swings inward and, with one exception, not outward. The third is the carve-out for certain antibody-drug conjugate intermediates, which relieves a specific and expensive licensing burden without relieving the quality obligations that sit around it.

Each of those has a commercial consequence. A company that has been running a global supply chain with China as a finishing and packaging site can now contemplate the reverse: bulk or intermediate manufacture onshore, with the regulatory footprint that follows. A company that has been waiting for the pilot to become permanent can plan investment against published criteria rather than against a negotiating position. And a company in the antibody-drug conjugate space can stop treating a mature small-molecule intermediate as if it needed a drug manufacturing licence, provided it can satisfy the conditions attached.

The draft also narrows as it clarifies. New applicants must be the holder’s own development or a development the holder participated in end to end. The first category has no post-approval change route, which means a product that is already on the market and falls only within that category cannot use this announcement to restructure its manufacturing after the fact. Reading the draft as a general liberalisation would misread it. It is a procedural consolidation with a deliberately bounded scope.

From pilot to standing procedure

The pilot that the draft replaces was launched in October 2024 for biologics. Its logic was experimental: take a small number of products, work out how a split manufacturing chain could be supervised, and learn from the cases. That model has real advantages when the regulator is still deciding what the standards should be. It has an obvious disadvantage when a company needs to commit capital: entry depends on a conversation, not on a rule, and the outcome of the conversation is not published.

A standing procedure changes the nature of the decision. Instead of asking whether a product might be allowed, a company asks whether it meets published conditions. The answer becomes auditable, and a negative answer becomes something that can be addressed — by changing the product scope, by changing the site configuration, or by choosing a different route.

The draft is structured as six parts and twenty-three articles. The parts follow the life of an application rather than the structure of the statute: general provisions, eligible products, the application and approval route, the holder’s obligations, cross-border arrangements, and supplementary provisions. That ordering is itself informative. Cross-border arrangements sit in a part of their own, near the end, which reflects the fact that they are treated as a distinct policy question rather than as one more variation on a domestic application.

The legal foundation is the revised Regulation for the Implementation of the Drug Administration Law, effective 15 May 2026. The Regulation settled the principle: a holder that genuinely needs to may entrust qualified enterprises with segmented production, subject to a unified quality assurance system covering the whole process and every site. What the Regulation did not do was specify which products qualify, what an application looks like, how licensing and registration interact, or what happens when a site is outside the country. Those are the questions the announcement answers.

The timing is not accidental. A pilot that expires on 31 December 2026 and a standing procedure that has not yet been finalised in mid-November leave a narrow window. Companies with products in the pilot need continuity; companies outside it need to know whether to prepare an application. The thirty-day comment period is short for a text of this density, which suggests the regulator is working to a fixed schedule and expects comment to be targeted rather than exhaustive.

There is also a signal in what the draft does not do. It does not extend segmented production to every product that could technically be split. It does not create a general right to commission manufacturing abroad. It does not remove the requirement for a drug manufacturing licence except in one defined case. The consolidation is real, but it is a consolidation of a narrow permission, not a broadening of it.

For companies, the practical difference between a pilot and a procedure shows up in the diligence file. Under a pilot, a legal opinion on manufacturing structure could describe the regulator’s practice and little more; under a procedure, it can cite a condition and test the facts against it. That shift is small in words and large in what it lets a board approve, because a condition can be assessed before money is committed, while a practice can only be assessed after a conversation that may or may not happen.

The four eligible categories

The draft lists four categories of product that may be produced in segments. The list is exhaustive, and a product that does not fall within one of the four cannot use the procedure however sensible the manufacturing logic may be.

The first category is innovative drugs whose production process or facilities and equipment carry special requirements. The wording points at products where the manufacturing itself is the constraint: a process that needs dedicated equipment, an environment that cannot be shared, a step that does not fit inside a general-purpose plant. For these products, splitting the chain is not a cost exercise but a feasibility one.

The second category covers drugs and vaccines that departments under the State Council have identified as clinically urgently needed, and drugs and vaccines needed for responding to public health emergencies or for reserve purposes. This is the category that carries the public-interest rationale most visibly. It also carries the most external dependency, because the identification comes from outside the drug regulator.

The third category is multi-valent and multi-component vaccines. The logic here is structural: a combination vaccine may require several antigen components, each with its own manufacturing chain, and consolidating all of them at a single site is not always realistic. Segmentation lets the components be made where they are best made and combined where the combination is validated.

The fourth category is the new one, and it is the one most likely to change behaviour. It covers an originator drug that has already obtained a marketing authorization in China, is manufactured outside the country, and has some or all of its steps transferred onshore for segmented production. In substance this is an onshoring route for products that are already approved. The product does not become a new drug; it becomes a product with a different manufacturing footprint.

The legal gateway for the fourth category is the third item of Article 32 of the Regulation, which leaves room for other drugs designated by the national drug regulator. The draft uses that room. The significance is procedural as much as substantive: it shows that the reserved category is not decorative, and that the regulator intends to use it to solve specific problems rather than to keep a general discretion in reserve.

Two limits sit on top of the four categories, and both point in the same direction. A new application for marketing must concern a product that the holder developed itself or in whose development the holder participated throughout. A licensee that acquired a product and now wishes to restructure its manufacturing does not automatically qualify. And the first category has no post-approval change entry at all: only products within the second, third and fourth categories may apply to change an existing authorization into a segmented arrangement.

The combined effect is a procedure that favours companies with an unbroken development history and a live pipeline. For a group that in-licenses assets into China and then looks for manufacturing flexibility, the draft offers less than a first reading might suggest. For a group that develops in China, or that developed globally and holds the full development record, the draft offers a route that did not previously exist in published form.

Two-track procedure and the sterile-experience threshold

An application runs on two tracks at once, and confusing them is the most common way to lose time.

The licensing track runs through the provincial drug regulator where the site is located. The holder, or the entrusted manufacturer, applies for the issue or the amendment of a drug manufacturing licence covering the site and the process. The licence is the permission to manufacture; it is not the permission to market the product made there.

The registration track runs through the drug evaluation centre for products not yet approved, and through the post-approval change framework for products already on the market. For the latter, the holder assesses the change category under the Measures for the Administration of Post-Approval Changes to Drugs (Trial) and files accordingly. A change in manufacturing site is not a uniform event: the same physical move can fall into a different category depending on the product, the process and the validation data. The classification determines the depth of review, and getting it wrong is a substantive error rather than a formatting one.

The two tracks are not sequential in a strict sense. Licensing work can proceed while the registration question is being resolved, and in practice it must, because a registration application that names a site without a licence is incomplete. But the two tracks answer to different reviewers, and a company that treats a licence amendment as the whole project will find itself with permission to manufacture a product it is not cleared to place on the market.

On organisation, the draft sets a principle rather than an absolute rule: the same process step should, in principle, be entrusted to one manufacturer. The principle is stated in the application and recorded in the approved process. The practical effect is that a holder cannot quietly split a single step between two contractors to manage capacity, and cannot move a step between contractors without the change being visible in the approved documentation.

Intermediates carry their own requirement. Where a product passes between sites in an unfinished state, the intermediate must have a clear quality standard that has been approved. This is the clause that turns a logistics arrangement into a regulatory object. An intermediate without an approved standard is not a legitimate handover point; it is an unregulated material in transit.

The sterile threshold is the hardest condition in the draft. For sterile products, at least one of the two parties — the holder or the entrusted manufacturer — must have three years or more of commercial production experience in the same dosage form. The requirement is deliberately relational: it does not demand that both sides be experienced, but it does demand that the experience exist somewhere in the pair. A new entrant cannot be paired with another new entrant, however strong their respective quality systems may look on paper.

The draft then addresses relaxations. A 2025 announcement, numbered 134, set out four situations in which the experience requirement could be relaxed. The draft recognises only the second and the fourth: the case where the parties sit within the same group under a unified quality system, and the case of an entrusted manufacturer that has been materially involved in developing the product and in manufacturing clinical trial supplies. The first and third relaxations are not carried over.

The omission is significant and easy to miss. A company that has been relying on one of the two excluded relaxations during the pilot should assume that the reliance does not survive into the standing procedure. Whether the final text restores them is a question worth putting in a comment, because the draft as published does not.

Where the holder’s obligations land

The draft distributes work but not responsibility. The holder remains the party answerable for the product, and the obligations listed in the text are written to make that answerability operational rather than nominal.

The first is presence. For each product in production, the holder must station two or more technical staff at the manufacturing site. This is not an audit visit and not a periodic review; it is a continuous presence during production. For a foreign holder using a domestic contractor, it means either seconding staff or contracting for a resident technical function that the regulator will treat as the holder’s own.

The second is audit. At least once a year, the holder must conduct a full-system GMP audit covering all manufacturing sites. The phrase “all sites” is the operative one: an audit programme that covers the domestic contractor but not the overseas site, or that covers the main site but not a site performing a single step, does not meet the requirement.

The third is the cold chain. Where bulk drug substance or another intermediate travels a long distance, the holder must validate the transport, monitor temperature, and inspect the material on arrival. The three obligations are cumulative. Validation without monitoring produces a document; monitoring without incoming inspection produces a record of a failure discovered too late.

The fourth is governance. A product quality risk consultation must be chaired by the legal representative or the enterprise head. Placing the chair at that level is a deliberate choice: it removes the possibility of treating a cross-site quality question as a technical matter settled below the level at which trade-offs are made.

The fifth is data. At steps where humans and machines interact, video data must be collected. The requirement reflects a supervisory reality: in a segmented chain, the reviewer cannot rely on walking the line, so the record of the line becomes the evidence. Companies should expect the retention, accessibility and integrity of that video to be examined alongside the batch records.

None of these obligations is novel in substance — a manufacturer operating a single site faces equivalents — but their combination is demanding for a chain that has been cut into pieces. The audit obligation looks outward to every site; the presence obligation looks inward to a single line; the data obligation looks backward at what actually happened. A holder that runs them as three separate programmes usually discovers, at the worst moment, that the evidence each produces does not line up.

Supervision follows the same logic. Provincial regulators are to manage on a basis described as one file per enterprise and one approach per product, with at least one GMP compliance inspection per product each year. For cross-province arrangements, the two sides are to notify each other periodically of inspection results, sampling results, adverse reaction information and major changes, and to conduct joint investigations or assist each other where a major risk emerges.

The cross-province mechanism deserves attention from foreign groups because it is where delay usually appears. A product split between two provinces has two supervisory relationships, and the notification duty is what keeps them from diverging. A holder that maintains its own parallel record of what each province has been told will find the arrangement easier to manage than one that relies on the two regulators to reconcile.

Cross-border arrangements: a one-way opening

The fifth part, spanning Articles 17 to 20, deals with arrangements that cross the border. It is the part most relevant to foreign holders, and it is the part where the draft is most explicit about direction.

Inbound is permitted. A foreign holder may entrust some or all of its process steps to segmented production inside China, provided the product falls within one of the four categories. The condition is not waived by the cross-border character of the arrangement; it is applied to it. A product that is not in one of the four categories does not become eligible because the holder is foreign.

Outbound is restricted. A domestic holder may not, in principle, entrust a foreign manufacturer with segmented production. The single exception is the fourth category, the originator drug that was approved in China while made abroad and is now being brought onshore. In that case the arrangement is the reverse of the general prohibition, because the product’s history already involves an overseas site.

The asymmetry is a policy choice, and it is worth stating plainly rather than reading a motive into it. The draft opens a route into the country and keeps the route out of the country closed except where a specific product history justifies it. Companies planning a regional manufacturing footprint should not assume that the inbound permission implies a reciprocal outbound one.

A group weighing an inbound arrangement should also look at its contract architecture earlier than it usually does. Joint liability shifts the risk allocation between the holder and the domestic party, and the annual audit of overseas sites shifts the cost base. Both are easier to negotiate before a licence annotation exists than after, because after the annotation the domestic party knows it cannot walk away without a regulatory consequence.

On documentation, the draft offers a practical concession. A cross-border application may use production qualifications and marketing authorization materials issued by domestic or foreign regulators to substitute for application materials that do not fit the arrangement. This matters most where a foreign site holds approvals that have no Chinese equivalent document. The concession is about form, not about substance: it does not reduce the quality standard, it reduces the paperwork that would otherwise be impossible to produce.

Annotation differs by direction, and the difference is operational. Where a foreign holder uses a domestic entrusted manufacturer, the arrangement is recorded on the copy of the domestic party’s drug manufacturing licence. Where a domestic holder commissions a foreign manufacturer, the foreign enterprise’s name, the site address and the product are recorded on both the original and the copy of the licence. The distinction reflects who holds the licence: the annotation follows the licensed entity.

The most consequential clause concerns responsibility. Where a foreign holder commissions segmented production inside China, a domestic responsible person performs the foreign holder’s obligations and bears joint liability. Joint liability is not a formality. It means the domestic party is exposed to the same regulatory consequences as the holder for failures in the arrangement, and it changes the negotiation of any contract that gives effect to the arrangement.

The audit obligation travels with it. The domestic responsible person must conduct at least one full-system GMP audit each year covering the overseas sites as well. For a foreign group, this is the clause that turns a Chinese entity into a genuine quality gate for global manufacturing, not merely a local representative. Groups should consider whether the entity they nominate has the technical depth and the mandate to audit a site it does not control.

The ADC carve-out

Article 22 addresses a problem specific to antibody-drug conjugates. The manufacturing chain for these products includes small-molecule intermediates that are chemically well characterised, stable in handling, and controllable in quality, and that play a decisive role in the quality and efficacy of the finished product. Some of these intermediates are not managed as drugs and not managed as active pharmaceutical ingredients.

Under a literal reading of the licensing rules, a site making such an intermediate could be treated as needing a drug manufacturing licence. The draft resolves the question by excusing the site from holding one, on conditions.

The conditions are cumulative. The site must comply with GMP. It must be inspected by the provincial regulator where the holder is located. The site and the process must be recorded on the licence. And the site remains subject to routine supervision and to extended supervision. Where the site is in another province, the provincial regulator at the site must additionally issue an opinion consenting to the entrusted production.

Read together, the carve-out is narrower than a headline reading suggests and more useful than a cautious one. It removes a licensing requirement that was poorly matched to the material, and it replaces it with an inspection and annotation regime that keeps the site inside the supervisory perimeter. The site does not become unregulated; it becomes regulated through the holder’s licence rather than through a licence of its own.

For groups with conjugates in development, the practical question is whether a given intermediate meets the description. Maturity of process, stability of physicochemical properties, controllability of quality, and criticality to quality and efficacy are the stated criteria. A company that wants the carve-out should be able to document each of them, because the inspection will ask for exactly that.

The clause also has a supply-chain consequence. Conjugation and payload manufacturing are often spread across specialist sites, some of which are not pharmaceutical facilities in the ordinary sense. The carve-out allows those sites to remain in the chain without each acquiring a licence, which reduces a structural barrier to locating conjugate work in China. It does not reduce the holder’s obligation to audit, to annotate, and to answer for the result.

Vaccines and the sequencing question

Vaccines appear in the second and third categories, and the draft adds a sequencing rule for a subset of them. Where the circumstances in Article 33 of the Regulation apply, the applicant must first seek approval from the national drug regulator under the Vaccine Administration Law, and only then proceed to licensing and registration.

The sequencing matters because it inverts the ordinary order of work. In a standard application, licensing and registration run in parallel with review. For the vaccines caught by Article 33, the approval comes first, and the licensing and registration steps follow it. A project plan that assumes parallel tracks will be wrong for these products, and the error will surface late.

The draft does not restate the substance of Article 33, and companies should read the Regulation directly rather than infer the scope from the announcement. What the announcement contributes is the procedural consequence: approval under the Vaccine Administration Law is a precondition, not a parallel filing.

What foreign holders should do before 30 November

The comment window closes on 30 November 2026, and the mailbox is the one named in the notice. A comment that identifies a specific article and a specific operational consequence is more likely to be useful than a general statement of support or concern. Four questions are worth answering internally before that date.

First, does the portfolio map onto the four categories, and onto which one? A product may appear to fit the first category because its process is unusual, while in fact fitting the fourth because its history is an overseas approval followed by an onshore transfer. The categories carry different consequences, including whether a post-approval change route exists at all.

Second, is the development history clean? For a new application, the holder must have developed the product itself or participated throughout. Groups that acquire assets should establish, before planning a segmented arrangement, whether the development record supports the claim. Where it does not, the route is closed regardless of the manufacturing logic.

Third, does the sterile experience sit on the right side? At least one party must hold three years of commercial experience in the same dosage form, and only two of the four relaxations are recognised. A group relying on an excluded relaxation should test the assumption now rather than at filing.

Fourth, who will be the domestic responsible person, and can that entity audit? Joint liability plus an annual full-system audit of overseas sites is a demanding combination. The entity needs technical capability, access to the sites, and a mandate that survives commercial pressure.

Beyond the four questions, three preparatory steps are worth taking. Map every site in the proposed chain against the licence annotation rules, because the annotation differs by direction and an omission is a defect. Confirm that each intermediate handover point has an approved quality standard, since an unapproved intermediate is not a valid boundary. And for conjugates, assemble the evidence that the intermediate meets each of the four criteria in Article 22, because the carve-out is granted on documentation and inspection rather than on description.

Outlook

The draft is a procedural document, and its effects will be felt in individual applications rather than in a single announcement. The parts most likely to be adjusted before the final text are the two excluded relaxations and the treatment of products whose development history is shared between an originator and a Chinese licensee. Both are the kind of question that a comment period exists to surface.

For planning purposes, the safe assumption is that the four categories, the two-track procedure, the one-way cross-border rule and the antibody-drug conjugate carve-out will survive in substance. The variables are the transitional arrangements for products currently in the pilot, and the precise wording of the experience requirement.

Companies with pilot products should treat the 31 December 2026 expiry as a real deadline and plan continuity rather than assume an automatic rollover. Companies without pilot products now have, for the first time, a published description of what a segmented arrangement looks like — which is itself the main change. The permission was always there in principle. What was missing was the procedure, and the procedure is now on the table for comment.

Sources

  • 国家药监局综合司·《关于药品委托分段生产有关事项的公告(征求意见稿)》征求意见页面(反馈截止 2026-11-30):https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20261113111413106.html
  • 中国政府网·国务院公报 2026 年第 4 号《中华人民共和国国务院令(第 828 号)中华人民共和国药品管理法实施条例》(2026-01-16 公布,2026-05-15 施行,含第三十二条分段生产条款):https://www.gov.cn/gongbao/2026/issue_12546/202602/content_7057461.html
  • 蒙城县人民政府(转载)·《中华人民共和国药品管理法实施条例》(2026 年修订,含第三十二条、第三十三条分段生产条款):https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

中国药品分段生产:从试点走向常规程序

为什么此刻值得看

2026 年 11 月 13 日,国家药监局综合司发布《关于药品委托分段生产有关事项的公告(征求意见稿)》。反馈截止 2026 年 11 月 30 日,意见投递到公告指定的邮箱。这份文本是征求意见稿,在正式稿印发之前不对任何人产生约束力,正式稿的措辞、范围以及对在审品种的过渡安排,都可能与现在不同。

让这份稿子值得现在读、而不是等到十二月再读的,是它背后的时间表。生物制品分段生产试点 2024 年 10 月启动,2026 年 12 月 31 日到期。新修订的《药品管理法实施条例》2026 年 5 月 15 日起施行。两个日期之间留着一道缝:条例给了分段生产的法律依据,但落地路径一直是试点,逐案商议,入口靠谈、不靠公布。这份公告要做的,就是把标准写下来。

用平实的话说,分段生产指的是同一个产品的不同生产工序分散在多个场地完成,有时还分散在多个法人主体手里,而这些场地与主体共同处在一套由上市许可持有人拥有的质量保证体系之下。它不是通常意义上的外包。持有人并没有随工序一起把责任交出去,它保留责任,只把工作分出去。这条区分,几乎决定了公告里的每一条。

对外资集团而言,这份稿子有三处值得注意。第一是第四类品种,它第一次为”已在境内获批、在境外生产”的原研药开出一条把部分或全部工序搬到境内、又不必按新药重新注册的路。第二是跨境条款的方向:门朝里开,除一种情形之外不朝外开。第三是抗体偶联药物某些中间产品的豁免,它卸掉了一项与物料性质并不匹配、代价却很高的许可负担,但并没有卸掉围绕着它的质量义务。

这三点各有商业含义。一家长期把中国当作成品加工与包装基地的全球企业,现在可以设想反过来做:把原液或中间产品放在境内生产,并接受随之而来的监管足迹。一家一直在等试点转正的企业,可以按公布的条件而不是按谈判地位来安排投资。而一家做抗体偶联药物的企业,可以不再把某个工艺成熟的小分子中间体当作需要药品生产许可的对象——前提是它能满足附在后面的条件。

这份稿子在澄清的同时也在收窄。新申请上市的品种,必须是持有人自主研发或者全程参与研发的。第一类没有上市后变更入口,也就是说,一个已经上市、且只落在第一类的产品,不能借这份公告在事后重组生产布局。把稿子读成一次普遍放开,是误读。它是一次程序上的收口,范围被有意画得很清楚。

从试点到常规程序

这份稿子接替的试点,2024 年 10 月针对生物制品启动。它的逻辑是试验性的:挑少量品种,摸索一条被切开的制造链该怎么监管,再从个案里学。在监管方还没决定标准应该是什么的时候,这种模式有实实在在的好处。但当企业需要押上资本时,它的短板也很明显:能不能进,取决于一次谈话;谈出什么结果,不会公布。

常规程序改变的是决策的性质。企业不再问”这个产品有没有可能被允许”,而是问”它是否满足已经公布的条件”。答案变得可核查,否定性的答案也变成可以处理的东西——调整品种范围、调整场地配置,或者换一条路走。

稿子的结构是六部分、二十三条。各部分的划分顺着一个申请的流程走,而不是顺着法条的体例走:总则、可分段品种、申请与审批、持有人义务、跨境安排、附则。这个次序本身带着信息。跨境安排单独成篇、位置靠后,说明它被当作一个独立的政策问题处理,而不是境内申请的一个变体。

法律基础是 2026 年 5 月 15 日施行的新修订《药品管理法实施条例》。条例把原则定了下来:确有需要的持有人可以委托符合条件的企业分段生产,前提是建立覆盖全过程、全部生产场地的统一质量保证体系。条例没有做的是:说明哪些品种够格、一份申请长什么样、许可与注册怎么衔接、场地在境外时怎么办。这些正是公告要回答的问题。

时间上的安排并非偶然。一个 2026 年 12 月 31 日到期的试点,加上一份十一月中旬还没定稿的常规程序,中间的窗口很窄。已在试点里的品种需要连续性,试点之外的品种需要知道要不要准备申报。对一份密度这么高的文本给出三十天反馈期,说明监管方按固定日程推进,并且预期意见是点对点的,而不是面面俱到的。

稿子没做什么,也是一种信号。它没有把分段生产扩展到所有技术上可以拆分的品种;它没有创设一项委托境外生产的普遍权利;除了一种明确情形,它没有免除药品生产许可。收口是真的,但收的是一项范围很窄的许可的口,而不是把它放宽。

对企业而言,试点与程序之间的实际差别,会出现在尽职调查文件里。试点之下,一份关于生产结构的法律意见只能描述监管惯例,再多也就到此为止;程序之下,它可以引用一项条件,并拿事实去比对。这个转变在字面上很小,在”董事会能批什么”上却很大——条件可以在掏钱之前评估,惯例只能在一场不知会不会发生的谈话之后评估。

四类可分段品种

稿子列出四类可以分段生产的品种。这份清单是穷尽式的,一个品种只要不落在这四类里,无论制造逻辑多么合理,都用不上这套程序。

第一类是生产工艺、设施设备有特殊要求的创新药。这个表述指向的是制造本身构成约束的产品:需要专用设备的工艺、不能共用的环境、塞不进通用厂房的一道工序。对这类产品,拆链不是成本问题,而是可行性问题。

第二类是国务院有关部门提出的临床急需药品及疫苗,以及应对突发公共卫生事件急需或者储备需要的药品及疫苗。这是公共利益理由最外显的一类。它同时也最依赖外部:认定来自药品监管系统之外。

第三类是多联多价疫苗。这里的逻辑是结构性的。一支联合疫苗可能要由几种抗原组分构成,每种组分各有自己的制造链,把它们全部塞进一个场地并不总是现实。分段让各组分在最适合的地方生产,再在组合工艺经过验证的地方完成组合。

第四类是新加的,也是最可能改变行为的一类。它指已取得境内上市许可、在境外生产、把部分或者全部工序转移至境内分段生产的原研药品。实质上,这是一条针对已获批产品的境内落地通道。产品不会因此变成新药,它只是换了一套生产足迹。

第四类的法律入口,是《实施条例》第三十二条第三项——为”国家局规定的其他药品”留的那道口子。稿子用掉了这道口子。意义一半在程序、一半在实体:它说明这项保留条款不是摆设,监管方打算用它解决具体问题,而不是留着一项笼统的裁量。

四类之上还压着两条限制,方向一致。新申请上市的品种,必须是持有人自主研发、或者全程参与研发的。一家把品种买进来、现在想重组生产的持证企业,并不自动够格。第一类则完全没有上市后变更入口:只有落在第二、第三、第四类的产品,才可以把已有的批件改成一种分段安排。

两条限制合起来,形成一套偏向”研发史完整、在研管线在手”的企业的程序。对一个把资产引进中国、再去找制造灵活度的集团来说,这份稿子给的东西比初读时感觉的要少。而对一个在中国做研发、或者在全球做研发并握有完整研发记录的集团来说,这份稿子给的是一条此前没有以公布形式存在的路。

两条线并行与无菌门槛

一份申请同时跑两条线,把两条线混为一谈,是最常见的误时方式。

许可线走场地所在地的省级药品监管部门。持有人或者受托生产企业,就场地与工艺申请《药品生产许可证》的核发或者变更。这张证是生产的许可,不是把那里生产出来的产品拿去上市的许可。

注册线走两条分支:尚未上市的品种报药品审评中心;已经上市的品种,按《药品上市后变更管理办法(试行)》走上市后变更。后一条分支里,持有人要先判定变更类别,再据以申报。生产场地的变化不是一件整齐划一的事:同样一次物理搬迁,因为品种、工艺、验证数据不同,可能落在不同类别。类别决定审评的深浅,判错类别是实体错误,不是格式错误。

两条线在严格意义上并不是先后关系。许可工作可以在注册问题解决的同时推进,实践中也必须如此,因为一份写明了场地却没有相应许可的注册申请是不完整的。但两条线面对的是不同的审评人,把许可证变更当成整个项目的企业,最后会拿到一张”可以生产、但不能上市”的许可。

在组织方式上,稿子给的是原则而不是铁律:同一道工序原则上委托一家生产企业。这条原则要在申请中说明,并在核准的工艺中载明。实际效果是,持有人不能为了调节产能把一个工序悄悄分给两家受托方,也不能在没有留下文件痕迹的情况下把一道工序从一家换到另一家。

中间产品有自己的要求。产品以未完成状态在场地之间流转的,中间产品必须有明确、且经过核准的质量标准。这一条把一项物流安排变成了监管对象。没有核准标准的中间产品,不是一个合法的交接点,而是一批处在监管真空里的物料。

无菌门槛是稿子里最硬的条件。对无菌药品,委托方与受托方之中至少一方,必须具备同剂型三年以上的商业化生产经验。这个要求是有意设计成”关系型”的:它不要求双方都有经验,但要求这份经验确实存在于这一对组合之中。两个新手凑在一起,无论各自的质量体系在纸面上多漂亮,都不行。

稿子接着处理放宽。2025 年的一份公告(第 134 号)列了四种可以放宽经验要求的情形。稿子只认其中第二项和第四项:双方同处一个集团、实行统一质量体系的;以及主要参与该药品研发、并生产过临床试验用药品的受托方。第一项与第三项没有沿用。

这个省略很重要,也很容易被忽略。在试点期间依赖那两项被排除的放宽情形的企业,应当假定这份依赖不会带进常规程序。正式稿会不会恢复,是一个值得写进意见的问题,因为按现在公布的文本,答案是否定的。

义务落在持有人身上

稿子把工作分了出去,但没有把责任分出去。持有人始终是对产品负责的一方,文本列出的义务,是为了让这份责任可执行,而不是停留在名义上。

第一项是在场。每个在产品种,持有人要在生产场地派驻两名以上技术人员。这不是一次审计访问,也不是一次阶段性复核,而是生产期间的持续在场。对使用境内受托方的境外持有人来说,这意味着要么派人,要么安排一项常驻的技术职能,而监管方会把这项职能视为持有人自己的。

第二项是审核。持有人每年至少开展一次覆盖全部生产场地的全体系 GMP 审核。”全部场地”是这句话的关键。一套只覆盖境内受托方、不覆盖境外场地的审核方案,或者只覆盖主场地、不覆盖承担单道工序场地的方案,都不满足要求。

第三项是冷链。原液或者其他中间产品长距离运输的,持有人要验证运输、监控温度,并在入厂时检验。三项义务是叠加的。做了验证不做监控,得到一份文件;做了监控不做入厂检验,得到一份”发现得太晚”的记录。

第四项是治理。产品质量风险会商必须由法定代表人或者企业负责人主持。把主持人定在这一层是有意的选择:它排除了把跨场地质量问题当成技术细节、在做出取舍的那一层之下解决的可能。

第五项是数据。在人机交互的环节,要采集视频数据。这条要求反映的是一种监管现实:在一条被切开的链上,检查员没法靠走线来确认,于是产线的记录就成了证据。企业应当预期,这些视频的留存、可调取性与完整性,会和批记录一起被看。

这几项义务单拎出来都不新鲜——只经营一个场地的生产企业面对的是同类要求——但叠在一条被切开的链上,要求就变得苛刻。审核义务朝外看,看的是每一个场地;在场义务朝内看,看的是某一条产线;数据义务朝后看,看的是当时到底发生了什么。把三者当成三个互不相干的项目的持有人,往往会在最糟糕的时候发现:三套证据对不上。

监督遵循同样的逻辑。省级监管部门按”一企一档、一品一策”管理,每个品种每年不少于一次 GMP 符合性检查。跨省安排的,两地要定期互相通报检查结果、抽检结果、不良反应信息与重大变更;出现重大风险的,联合调查或者相互协查。

跨省机制值得外资集团多看一眼,因为拖延通常就出在这里。一个跨两省的产品有两段监管关系,而通报义务是防止两段判断分叉的东西。自己另建一份”哪个省被告知了什么”的台账的持有人,会比指望两地监管方自行对账的持有人更省事。

跨境安排:只朝一个方向开

第五部分(第十七条至第二十条)处理跨越关境的安排。这是与境外持有人最相关的一部分,也是稿子把方向讲得最明白的一部分。

进来可以。境外持有人可以把部分或者全部工序委托境内分段生产,前提是品种落在四类之中。这个条件不会因为安排具有跨境性质而免除,而是被适用到跨境安排上。不在四类里的品种,不会因为持有人是境外的就变得够格。

出去受限。境内持有人原则上不得委托境外生产企业分段生产。唯一的例外是第四类——那个在境内获批、在境外生产、如今正在往境内搬的原研药。这种情形下,安排本身就是一般禁令的反面,因为产品的历史里本来就有一个境外场地。

这种不对称是一项政策选择,值得平实地陈述,而不必去揣测动机。稿子开了一条进国的路,同时把出国的路关着,只在特定产品历史足以支撑时例外。规划区域制造布局的企业,不应当从”进来可以”推出”出去也可以”。

考虑把工序搬进来的集团,还应当比惯常更早去看合同架构。连带责任改变的是持有人与境内一方之间的风险分配,对境外场地的年度审核改变的是成本结构。两件事在许可证载明之前谈,都比在载明之后谈容易——载明之后,境内一方清楚自己没有退路,因为退出本身就是一项监管后果。

在材料上,稿子给了一项务实的让步。跨境申请可以用境内、境外监管部门出具的生产资质与上市许可材料,替代那些不适用于该安排的申请材料。这在境外场地持有境外批件、而该批件在境内没有对应文件时最有用。这项让步是形式上的,不是实体上的:它不降低质量标准,只是减少了本来无法产出的那部分纸面工作。

载明方式按方向不同,而这个差别是操作性的。境外持有人委托境内生产的,在境内受托方《药品生产许可证》副本上载明。境内持有人委托境外生产的,境外企业名称、场地地址、产品要在许可证正本与副本上同时载明。区别的来源是谁持证:载明跟着持证主体走。

最有分量的条款是责任。境外持有人跨境委托境内分段生产的,由境内责任人履行境外持有人的义务,并承担连带责任。连带责任不是手续。它意味着境内一方要为这项安排中的失误承担与持有人同等的监管后果,也意味着任何落实这项安排的合同,谈判方式都要改。

审核义务随之同行。境内责任人每年至少要做一次覆盖境外场地的全体系 GMP 审核。对境外集团来说,这一条把一家中国主体变成了全球制造体系里一道真实的质量关口,而不只是一个本地代表处。集团需要考虑:拟指定的这家主体,有没有技术深度和授权去审核一个它并不控制的场地。

抗体偶联药物的例外

第二十二条处理的是抗体偶联药物特有的一个问题。这类产品的制造链里有小分子中间体,化学性质清楚、处置中稳定、质量可控,并且对成品的质量与疗效起关键作用。其中一些中间体既不按药品管理,也不按原料药管理。

按许可规则的直白读法,生产这种中间体的场地可能被当作需要药品生产许可证。稿子用”附条件豁免”回答了这个问题。

条件是叠加的。场地要符合 GMP;要经持有人所在地省级监管部门检查;场地与工艺要在许可证上载明;场地仍要接受日常监管与延伸监管。场地在另一省的,还须由场地所在地省级监管部门出具同意受托生产的意见。

合起来读,这项例外比标题式读法要窄,也比保守式读法要有用。它卸掉了一项与物料性质并不匹配的许可要求,换上一套检查加载明的安排,把场地留在监管边界之内。场地不会因此变成无人监管,它变成通过持有人的许可证接受监管,而不是自己持一张证。

对有偶联药物在研的集团来说,实际问题是一项给定的中间体是否落入这个描述。工艺成熟、理化性质稳定、质量可控、对质量疗效起关键作用,是文本给出的四项标准。想要用上这项例外的企业,应当能为每一条留下文件,因为检查要的正是这些。

这一条还有供应链上的后果。偶联与载荷的生产常常分散在专业场地之间,其中一些并不是通常意义上的制药车间。例外让这些场地可以留在链上而不必各自去拿一张证,从而降低了把偶联环节放在境内的结构性障碍。它不降低持有人的审核、载明与最终担责义务。

疫苗与先后顺序

疫苗出现在第二类和第三类里,稿子又为其中一个子集加了顺序规则。符合《实施条例》第三十三条情形的,要先按《疫苗管理法》向国家药监局申请批准,再办许可与注册。

这个顺序之所以重要,是因为它把通常的工作次序倒了过来。在一般申请里,许可与注册同审评并行推进。对落入第三十三条的疫苗,批准在前,许可与注册在后。按并行双线做的项目计划,在这些品种上是错的,而错误会在很晚的时候才暴露。

稿子没有复述第三十三条的实体内容。企业应当直接去读条例,而不是从公告反推适用范围。公告贡献的是程序后果:按《疫苗管理法》取得批准,是前置条件,不是一条并行的申报。

境外持有人应在 11 月 30 日之前做什么

反馈窗口 2026 年 11 月 30 日关闭,邮箱是公告里写明的那个。点名到具体条文、并说明具体操作后果的意见,比泛泛的支持或担忧更有用。在此之前,有四个问题值得先在内部回答清楚。

第一,产品组合落在四类的哪一类?一个产品可能看起来像第一类,因为工艺特殊;实际上却属于第四类,因为它的历史是”境外获批、再往境内搬”。不同类别的后果不同,包括到底有没有上市后变更入口。

第二,研发史是否干净?新申请上市,持有人必须自己研发、或者全程参与研发。收购资产的企业,在规划分段安排之前,应先确认研发记录能否支撑这个主张。支撑不了,无论制造逻辑多顺,路都是关着的。

第三,无菌经验是否落在对的一侧?至少一方要有同剂型三年以上商业化生产经验,而四项放宽只有两项被承认。依赖被排除的那两项的企业,现在就应当检验这个假设,而不是等到申报。

第四,境内责任人是谁,它审得动吗?连带责任加上对境外场地的年度全体系审核,是很硬的一组要求。这家主体需要技术能力、需要能进入那些场地、还需要一份不会被商业压力磨掉的授权。

四个问题之外,还有三件准备工作值得做。把拟设链条上的每个场地对照许可证载明规则过一遍,因为载明方式按方向不同,漏一处就是缺陷。确认每一个中间产品交接点都有核准的质量标准,因为没有核准标准的中间产品不是一个有效的边界。做偶联药物的,把中间体满足第二十二条四项标准的证据攒起来,因为这项例外是凭文件与检查给出的,不是凭描述给出的。

展望

这是一份程序性文件,它的效果会体现在一个个具体申请里,而不是体现在某一次发布里。正式稿最可能调整的地方,是那两项被排除的放宽情形,以及研发史由原研方与境内被许可方共享的品种怎么处理。这两类问题,正是反馈期存在的理由。

做规划时,稳妥的假设是:四类品种、双线程序、单向跨境、抗体偶联药物例外,在实体上会保留下来。变量在于试点内品种的过渡安排,以及经验要求的具体措辞。

手上有试点品种的企业,应当把 2026 年 12 月 31 日当作真实期限,按”需要接续”来准备,而不是假定会自动顺延。没有试点品种的企业,第一次拿到了一份关于”分段安排长什么样”的公开描述——这本身就是主要的变化。许可在原则上一直存在。缺的是程序,而程序现在摆上了桌面,等着被评论。

来源

  • 国家药监局综合司·《关于药品委托分段生产有关事项的公告(征求意见稿)》征求意见页面(反馈截止 2026-11-30):https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20261113111413106.html
  • 中国政府网·国务院公报 2026 年第 4 号《中华人民共和国国务院令(第 828 号)中华人民共和国药品管理法实施条例》(2026-01-16 公布,2026-05-15 施行,含第三十二条分段生产条款):https://www.gov.cn/gongbao/2026/issue_12546/202602/content_7057461.html
  • 蒙城县人民政府(转载)·《中华人民共和国药品管理法实施条例》(2026 年修订,含第三十二条、第三十三条分段生产条款):https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

Shipping Insurance Guidance: What Seven Ministries Set Out for Cover, Clauses and Pricing

  • Seven ministries released the Guidance on Accelerating the High-Quality Development of Shipping Insurance on 6 November 2026.
    2026 年 11 月 6 日,七部委联合印发《关于加快航运保险高质量发展的指导意见》。
  • The document sets five tasks: stronger cover, a more competitive market, better claims, stricter supervision and a sounder operating environment.
    文件提出五方面任务:提升保障水平、增强国际竞争力、优化理赔服务、推进严监管强监管、健全运行机制。
  • It calls for developing Standard Clauses for Shipping Insurance, expanding the use of the renminbi and strengthening independent pricing capability.
    文件提出制定航运保险标准条款、扩大人民币使用、提升自主定价能力。
  • Insurers are encouraged to pursue Risk Reduction and to build a Global Service Network for cross-border claims.
    文件鼓励保险机构开展风险减量,并加强全球综合服务网络建设。
  • High-value vessels and offshore equipment should carry cover across design, construction, operation and disposal.
    高价值船舶与海工装备应建立覆盖设计、建造、营运、处置等全生命周期的保险方案。
  • Geopolitical conflict, supply chain interruption, cyber security and ice navigation are named as priorities for product development.
    地缘政治冲突、供应链中断、网络安全、冰区航行被列为产品研发的重点方向。

Shipping Insurance Guidance: What Seven Ministries Set Out for Cover, Clauses and Pricing | 航运保险指导意见:七部委在保障、条款与定价上说了什么

Overview

On 6 November 2026 seven central departments jointly released the Guidance on Accelerating the High-Quality Development of Shipping Insurance: the National Financial Regulatory Administration, the Ministry of Transport, the National Development and Reform Commission, the Ministry of Finance, the Ministry of Commerce, the People’s Bank of China and the State-owned Assets Supervision and Administration Commission of the State Council.

The document is a guidance opinion. It sets a direction, lists tasks and assigns them to regulators and to the industry. It opens no application window, creates no licence and attaches no subsidy to a named activity. Read as a statement of where the market is heading — standard clauses, renminbi denomination, independent pricing — it tells a company how to align its programme.

What kind of document this is

Policy instruments are graded, and the grade decides what a company can do with the text. A catalogue or a negative list changes what is permitted; a guidance opinion does not. It sets an objective, lists tasks, and leaves the operative rules to the regulators who must draft them.

The distinction matters for three items — standard clauses, renminbi use and independent pricing. Each is written as something to be developed, not as something in force. Until the clauses are issued, the terms of a policy remain the terms the parties negotiate.

The five tasks in brief

Cover. A risk management system across a vessel’s whole life, a better mechanism for cargo in transit, and a larger supply of capacity.

Market and competitiveness. Develop standard clauses, expand renminbi use, strengthen independent pricing capability and deepen exchanges with foreign markets.

Claims. Better quality and efficiency, encouragement of risk reduction, and a global service network that lifts the standard of service abroad.

Supervision. Product management rules, conduct rules for brokers, and clearer responsibility for risk control inside insurers.

Environment. Support mechanisms, a crackdown on irrational competition, and a training system.

Together, the headings describe a market that prices its own risks rather than imports a price.

Clauses, currency and pricing

Standard clauses matter because a marine policy is assembled from clauses, and a clause recognised by both the insurer and the reinsurer behind it is easier to place. Where wording is standardised, a dispute becomes a dispute about facts.

Renminbi use matters because a shipping company’s revenue and a manufacturer’s freight cost are increasingly denominated in renminbi while the cover is not. A policy written in the settlement currency removes one basis risk from the hedge.

Independent pricing matters because a market that can price its own risks can also retain them. The guidance pairs pricing capability with retained capacity: insurers and the China Shipowners Mutual Assurance Association are asked to raise retained limits.

Cover across an asset’s life

Shipbuilders and shipping companies are asked to use insurance tools actively to disperse risk as they pursue greener and more digital operations, and to use the ship survey and evaluation mechanism to build programmes covering design, construction, operation and disposal for high-value vessels and offshore equipment. The list is specific: oil tankers, liquefied natural gas carriers, large container ships, large cruise ships, large bulk and ore carriers, and yachts.

For a company importing or building such an asset in China, the practical change is the unit of cover. A cargo policy covers a voyage; a lifecycle programme covers a shipyard delay, a construction period, a delivery voyage, an operating loss and a disposal. The gaps between those policies are where uninsured losses live.

The new risk list

New energy and clean energy vessels are to be supported with cover along the industrial chain — green fuel bunkering, battery system replacement, green retrofit and operational safety. Smart ships with autonomous navigation and remote control are to strengthen cover for emerging risks such as cyber security.

The document then names what a basic cargo policy does not reach: geopolitical conflict, logistics and supply chain interruption, cyber security, and ice navigation. It asks the market to optimise products for these in response to demand, and to speed up development for cross-border e-commerce and commodities.

What it means for pharmaceutical and cold-chain shippers

A pharmaceutical importer’s exposure is usually not the hull but the container. Temperature deviation, a broken cold chain, a delay at a transhipment port — these are cargo risks with a liability question attached, and the emphasis on claims and risk reduction speaks to them.

Two cautions apply. The standard clauses are being developed, not issued, so a contract today still rests on negotiated terms and on the actual policy wording. And the guidance does not address pharmaceutical market access: hospital investment, drug registration and device approval are separate regimes.

Practical steps

  • Read the programme as a chain — cargo, construction, installation, trial operation, operating loss, disposal — and mark where one policy ends and the next begins.
  • Ask where retained capacity sits and how much risk is ceded; a low premium behind a thin reinsurance tower is a price, not cover.
  • Align the insurance schedule with the customs and installation schedule; a week between discharge and installation is uninsured.
  • Match the currency of the policy to the currency of the loss; a renminbi policy and a dollar claim leave an unhedged exposure.
  • Keep the evidence chain for a cross-border claim: survey report, temperature log, notice of loss, and the letters showing when the carrier was told.

Outlook

Expect implementing rules on product management and broker conduct, and industry work on the standard clauses.

Sources

  • 国家金融监督管理总局·七部委《关于加快航运保险高质量发展的指导意见》新闻稿:https://www.nfra.gov.cn/cn/view/pages/ItemDetail.html?docId=1278246
  • 商务部·七部委联合印发《关于加快航运保险高质量发展的指导意见》:https://www.mofcom.gov.cn/syxwfb/art/2026/art_59e15dddb16b49559d6cc9253377493a.html
  • 国家金融监督管理总局·《关于加快航运保险高质量发展的指导意见》全文:https://www.nfra.gov.cn/cn/view/pages/ItemDetail.html?docId=1278317&itemId=928
  • 中国政府网·国务院政策文件库:https://www.gov.cn/

航运保险指导意见:七部委在保障、条款与定价上说了什么

概述

2026 年 11 月 6 日,七部委联合印发《关于加快航运保险高质量发展的指导意见》。印发单位为金融监管总局、交通运输部、国家发展改革委、财政部、商务部、中国人民银行、国务院国资委。

这是一份指导意见。它讲方向、列任务,把任务分派给监管部门和行业。它没有开放申报窗口,没有创设许可类别,也没有把补贴绑定到某一项具体活动上。如果把它读成”可以来申请优惠”,会发现没有表格可填;如果把它读成”市场往哪里走”的说明——标准条款、人民币计价、自主定价——那它现在就能告诉我们,应当怎样把自身的保险安排往这个方向对齐。

这是一份什么性质的文件

政策工具是分层的,层级决定了企业能拿这份文本做什么。目录、负面清单这类工具改变的是”允许做什么”,指导意见不改变这些。它设定目标、列出任务,把可执行的规则留给必须起草细则的监管部门。

这一区分对三项有商业分量的内容最关键——标准条款、人民币使用、自主定价。三者都写成”要制定””要扩大””要提升”,而不是”已经生效”。在条款起草发布之前,一份保单的条款仍然是双方谈出来的条款。

五方面任务概要

保障。 健全船舶全生命周期风险管理体系,完善货物运输风险保障机制,扩大航运保险保障供给。

市场与竞争力。 制定航运保险标准条款,扩大人民币使用,提升自主定价能力,深化对外交流合作。

理赔。 改进理赔服务质效,鼓励风险减量,加强全球综合服务网络建设,提升全球服务水平。

监管。 完善航运保险产品管理机制,规范航运保险经纪行为,严格落实监管职责,压实企业风险防控主体责任。

环境。 优化业务支持机制,整治非理性竞争,健全人才培养体系,细化配套支持政策。

五个方面合起来,描述的是一张自己给自己的风险定价、而不是进口一个价格的市场。

条款、币种与定价

标准条款之所以重要,是因为海上保单是由一条条条款拼装起来的文件,而一条同时被保险人和其背后的再保险人认得的条款,更容易分出。措辞一旦标准化,争议就从”这句话什么意思”变成”事实是什么”。

人民币使用之所以重要,是因为航运公司的收入与制造企业的运费正越来越多地以人民币计价,而保单不是。用结算币种书写的保单,从对冲里去掉了一重基差风险。

自主定价之所以重要,是因为能给自己风险定价的市场,也就能把风险留在自己手里。文件把定价能力与自留能力放在一起:推动保险公司与中国船东互保协会合理提升自留风险额度。

覆盖资产全生命周期

文件要求船舶制造企业、航运企业在推动绿色化、数智化发展的过程中,主动运用保险工具分散风险;要求充分利用船检评估机制,推动高价值船舶与海工装备健全覆盖设计、建造、营运、处置等全生命周期的保险管理方案。列举的船型是具体的:油轮、液化天然气船、大型集装箱船、大型邮轮、大型散矿船、游艇。

对在中国进口或建造这类资产的企业,实际变化是”保障单位”。一张货运险保单保的是一段航程;一套全生命周期方案保的是船厂延期、建造期、交付航程、营运损失与处置。这些保单之间的缝隙,正是没有保险的损失所在。

新的风险清单

新能源清洁能源船舶,要提升对绿色燃料加注、电池系统更换、绿色改装、运营安全等相关产业链的保险保障水平。具备自主航行、远程控制能力的智能船舶,要强化网络安全等新兴风险保障。

文件随后点出了基本货运险够不到的风险:地缘政治冲突、物流和供应链中断、网络安全、冰区航行。它要求市场响应需求、优化这些特殊和新型风险的产品供给,并加快跨境电商等新业态及大宗商品等重点领域的保险产品研发推广。

对医药与冷链货主意味着什么

医药进口方的暴露通常不在船壳,而在集装箱。温控偏差、冷链断链、转运港延误——这些是货物风险,同时挂着一个责任问题;文件对理赔质量和风险减量的强调,正对着这些场景。

两点需要提醒。标准条款正在制定、尚未发布,所以今天的合同仍要靠谈出来的条款和保单实际措辞。另外,文件不涉及医药市场准入:医院投资、药品注册、器械审批是另外的制度。

落地步骤

  • 把保险安排当链条读:货运、建造、安装、试运行、营运损失、处置,并标出上一张保单在哪里结束、下一张从哪里开始。
  • 向经纪人问清自留能力放在哪里、分出了多少风险;保费便宜而再保层级单薄,那是一个价格,不是一份保障。
  • 大型设备进口时,把保险排期与报关、安装排期对齐;卸船到安装之间空出的一周,就是没有保险的一周。
  • 让保单币种与损失币种一致;人民币保单配美元索赔,会留下一重没有对冲的折算暴露。
  • 跨境索赔留好证据链:检验报告、温度记录、损失通知,以及能够证明何时已告知承运人的往来函件。

展望

可以预期监管部门会就产品管理与经纪行为出台实施细则,行业层面会推进标准条款的起草。方向已经足够清晰,可以据此规划。

来源

  • 国家金融监督管理总局·七部委《关于加快航运保险高质量发展的指导意见》新闻稿:https://www.nfra.gov.cn/cn/view/pages/ItemDetail.html?docId=1278246
  • 商务部·七部委联合印发《关于加快航运保险高质量发展的指导意见》:https://www.mofcom.gov.cn/syxwfb/art/2026/art_59e15dddb16b49559d6cc9253377493a.html
  • 国家金融监督管理总局·《关于加快航运保险高质量发展的指导意见》全文:https://www.nfra.gov.cn/cn/view/pages/ItemDetail.html?docId=1278317&itemId=928
  • 中国政府网·国务院政策文件库:https://www.gov.cn/

Medical Device GMP: How the Four New Inspection Principles Judge Conformity

  • China’s revised Medical Device GMP took effect on 1 November 2026, together with four supporting inspection principles issued by the NMPA on 23 October 2026.
    新修订的《医疗器械生产质量管理规范》自 2026 年 11 月 1 日起施行,国家药监局已于 2026 年 10 月 23 日印发四个配套检查指导原则。
  • The principles cover Sterile Devices, implantable devices, In Vitro Diagnostic Reagents and customised dentures, replacing the 2015 and 2016 on-site principles on the same date.
    四个指导原则覆盖无菌医疗器械、植入性医疗器械、体外诊断试剂和定制式义齿,并于同日废止 2015 年、2016 年的现场检查指导原则。
  • From 1 November 2026, production licence verification and post-market supervision inspections for these four families are judged against the new principles.
    自 2026 年 11 月 1 日起,这四类产品的生产许可核查与上市后监督检查,均按新指导原则进行结果判定。
  • Inspection items are graded into Critical Items, major items and general items by each clause’s importance in the quality system and the risk its non-compliance creates.
    检查项目按各条款在质量管理体系中的重要性及不符合带来的风险,划分为关键项目、主要项目、一般项目三个等级。
  • The principles merge the GMP with its annexes and convert the combined text into inspection items, so the annex is no longer read on its own.
    指导原则是把规范与相应附录融合衔接、转化形成检查项目,附录不再作为单独文本另行对照。
  • A failed Critical Item normally means the inspection fails outright, but that is settled inspection practice rather than a rule written into these documents.
    关键项目不合格通常直接判定不通过,但这是检查实务的通行做法,不是这四份文件写明的条文。
  • New applicants and long-held licence holders are measured on the same new scale, so gap analysis cannot wait for the next renewal.
    新办证与老持证企业适用同一把新尺子,差距分析不能等到下一次换证。

Medical Device GMP: How the Four New Inspection Principles Judge Conformity | 医疗器械 GMP:四个新检查指导原则如何判定符合性

Overview

On 23 October 2026 the National Medical Products Administration issued four inspection principles to accompany the revised Medical Device Good Manufacturing Practice, which takes effect on 1 November 2026. The four cover sterile medical devices, implantable medical devices, in vitro diagnostic reagents and customised dentures, and they take effect on the same day as the revised GMP.

The notice also repeals what came before: the 2015 on-site inspection principles for sterile, implantable and IVD production (Shi Yao Jian Xie Jian [2015] No. 218) and the 2016 principles for customised dentures (Shi Yao Jian Xie Jian [2016] No. 165).

Why the annexes were folded in

The drafting method is stated plainly. Each principle takes the GMP and the corresponding annex — sterile, implantable and so on — merges them, and converts the combined text into inspection items. The annex stops being a separate document read beside the GMP; it becomes part of the checklist.

That changes how a quality team holds its documentation. A system that mapped its procedures to the GMP and treated the annex as a second layer now has one layer, and the mapping must be rebuilt rather than relabelled.

Who is measured on the new scale

Four product families: sterile devices, implantable devices, IVD reagents and customised dentures. Both production licence verification — new applications and scope changes — and post-market supervision inspections use the new principles to determine results.

That second channel is the one companies underestimate. A licence holder that passed verification years ago is not exempt; the next supervision inspection applies the same new scale. Contract manufacturers sit inside the same perimeter, because the rules attach to the production activity rather than to the brand on the label, and a customer audit does not substitute for the regulator’s.

For a foreign group, the exposure sits in Chinese plants making these four families, whether wholly owned or in a joint venture. A plant outside them is untouched by the four principles but still bound by the GMP itself.

What the three grades do

The notice states that items are graded into critical, major and general according to each clause’s importance in the quality system and the risk created when it is not met. The grading is a risk statement rather than a scoring system: it tells an inspector which findings can be tolerated and which cannot.

One point needs care. Practice treats a failed critical item as a failed inspection. That is the settled approach in GMP inspection, not a sentence in these four documents, and it should be attributed to practice rather than to the notice.

Preparing for an inspection under the new scale

A supervision inspection that arrives unannounced is the wrong moment to discover that the quality manual still cites a repealed on-site principle. Three artefacts are worth assembling before the inspection rather than during it.

The first is a clause map: for each critical item in the merged checklist, the internal procedure that satisfies it, its version date, and the person accountable. A map that cannot be produced within a day is not finished, because it is the document an inspector will ask for first.

The second is a change log for the two years before the inspection, covering process, supplier and equipment changes in the four families. A sterilisation parameter altered without revalidation reads as an unvalidated process, not as an administrative gap.

The third is the contract manufacturing chain. Where a foreign group uses a Chinese contract manufacturer, the group’s own quality agreement should already allocate responsibility for the merged items; if the agreement predates the merged checklist, it allocates responsibility for a document that no longer exists.

None of this is a legal requirement in the notice. It is the working order in which inspectors tend to ask, and preparing in that order shortens the inspection rather than the requirements.

Where the four lines differ

The four principles share a structure but not a weak point. For sterile devices the recurring failures cluster around cleanroom environment monitoring, sterilisation process validation and sterile barrier packaging validation. For implantable devices the pressure falls on traceability, from raw material to the finished device. For IVD reagents it falls on raw material and calibrator management, where a supplier change can move a result. For customised dentures it falls on the patient model and on material traceability, because each unit is made to an individual.

These are listed by product logic, not by clause number; the documents are the authority on which item sits in which grade.

A practical timetable

  • Complete a gap analysis now, not at renewal; the new scale already applies.
  • Convert the quality manual and any procedure citing the annex, then re-map to the merged items.
  • Run an internal audit using the three-grade logic, so that findings are ranked the way an inspector will rank them.
  • Re-evaluate suppliers whose materials feed a critical item, especially IVD raw and implantable materials.
  • Keep the annual self-inspection for products already licensed, and record it against the new item structure.

What this does not change

This is a production-end instrument. It does not alter registration or filing requirements, does not open a new channel and does not change how a device is cleared for the market. A registered device needs no new filing; what changes is how its factory is inspected.

Teams that read the four principles as a registration document will spend a quarter on the wrong file; teams that track registration only meet the risk on inspection day.

Outlook

Expect inspection reports to cite merged clauses rather than annex paragraphs, and expect internal document maps that still separate the GMP from its annexes to look dated within a year. The substantive requirements have not been rewritten; what changed is where they are written down and how findings are graded.

The practical test of readiness is simple: ask the quality head for the clause behind each critical item. If the answer is a page in an annex that no longer stands alone, the conversion has not been done.

Related reading

  • *Brain-Computer Interface Devices: Registration Pathways* (Article 454) — the registration side for an emerging device category.

Sources

  • 国家药监局·关于印发无菌医疗器械等四个检查指导原则的通知:https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjylqx/20261028170125118.html
  • 国家药品监督管理局:https://www.nmpa.gov.cn/
  • 中国政府网:https://www.gov.cn/
  • 国家市场监督管理总局:https://www.samr.gov.cn/

医疗器械 GMP:四个新检查指导原则如何判定符合性

概述

2026 年 10 月 23 日,国家药监局印发四个检查指导原则,配套新修订的《医疗器械生产质量管理规范》实施。规范自 2026 年 11 月 1 日起施行,四个指导原则同日施行。

四个指导原则分别对应无菌医疗器械、植入性医疗器械、体外诊断试剂和定制式义齿。通知同时废止了原国家食品药品监督管理总局印发的三个现场检查指导原则(食药监械监〔2015〕218 号),以及定制式义齿现场检查指导原则(食药监械监〔2016〕165 号)。废止与施行同日完成,中间没有并行期。

附录为什么被并了进去

编制方法在通知里写得很直白:把规范与相应附录融合衔接,转化形成检查项目。附录不再是放在规范旁边单独对照的文本,而成为检查表的一部分。

这会改变质量团队管理文件的方式。过去把程序文件对应到规范、再把附录当作第二层的体系,现在只剩一层,对应关系需要重建,而不是换个标签。做过一次完整映射的团队会发现,真正的工作量在条款对应,不在文字改写。

谁在被用新尺子量

四类产品:无菌医疗器械、植入性医疗器械、体外诊断试剂、定制式义齿。生产许可核查与上市后监督检查,都按新指导原则进行结果判定。

第二条渠道最容易被低估。多年前通过核查的持证企业并不豁免,下一次监督检查用的就是同一把新尺子。受托生产企业也在同一范围内,因为规则约束的是生产活动,而不是标签上的品牌;客户审核替代不了监管检查。

对外资集团而言,敞口集中在境内生产这四类产品的工厂,无论独资还是合资,也包括为集团产品线供货的本地基地。不生产这四类产品的工厂不受这四个指导原则约束,但仍受规范本身约束。

三个等级起什么作用

通知明确,检查项目按各条款在质量管理体系中的重要性以及不符合所带来的质量安全风险程度,划分为关键项目、主要项目、一般项目三个等级。分级是风险表述,不是打分制度:它告诉检查员哪些缺陷可以容忍,哪些不能。

写给董事会的材料里有一点要留神。实务中,关键项目不合格通常直接判定不通过。这是 GMP 检查的通行做法,不是这四份文件写明的条文,引用时应当归到实务,而不是归到通知。

按新尺子准备一次检查

等监督检查上门那天才发现质量手册还在引用已废止的现场检查指导原则,是最糟糕的时点。有三样东西值得在检查之前备好,而不是在检查当中去找。

第一份是条款对应表:合并后清单上的每一个关键项目,对应哪一份内部程序、版本日期、责任人是谁。一份一天之内拿不出来的对应表等于还没做完,因为这是检查员最先要的文件。

第二份是检查前两年的变更台账,覆盖这四类产品的工艺、供应商与设备变更。灭菌参数改了却没有再确认,在检查里读作”工艺未确认”,而不是”记录不全”。

第三份是受托生产链条。外资集团若使用境内受托生产企业,集团自身的质量协议里就应当已经就合并后的检查项目划分了责任;如果协议签署早于合并清单,它划分的是一份已经不存在的文件上的责任。

这些都不是通知里的法定要求。它们只是检查员通常的问询顺序,按这个顺序准备,缩短的是检查过程,而不是要求本身。

四条线的差别在哪里

四个指导原则结构相同,薄弱点不同。无菌器械的重复性问题集中在洁净区环境监测、灭菌过程确认和无菌屏障包装验证。植入性器械的压力落在可追溯性上,从原材料一直到成品。体外诊断试剂落在原料与校准品管理,供应商一换,结果就可能漂移。定制式义齿落在医患模型与材料溯源,因为每一件都是按个人定制。

这些是按产品逻辑列的,不是按条款号列的。哪一项属于哪个等级,以文件本身为准;把行业经验当成条文引用,是这类文章最常见的错误。

没有改变什么

这是生产端的文件。它不改变注册与备案要求,不新设申请通道,也不改变产品如何获准上市。产品已经注册的企业,不需要为此新交一份申请;改变的是工厂如何被检查。

把四个指导原则当成注册文件来读的团队,会把一个季度花在错误的材料上。反过来,只盯注册进度、不更新体系文件的团队,风险要到检查那天才显现。

一份可执行的时间表

  • 现在就对着四个指导原则做差距分析,不要等到换证;新尺子已经生效。
  • 换版质量手册,以及那些引用了附录的程序文件,再把它们重新对应到合并后的检查项目。
  • 用三个等级的逻辑做一次内审,让自查发现的问题按检查员的方式排序。
  • 对供应关键项目物料的上游做再评价,体外诊断原料与植入材料尤其如此。
  • 对已取证产品继续做年度自查,并按新的项目结构留痕。

展望

可以预期检查报告将引用合并后的条款,而不是附录段落;那些仍把规范与附录分开管理的内部文件地图,一年之内就会显得过时。实质性要求并没有重写,改变的是它们写在哪里、以及缺陷如何分级。

检验准备程度有一个很简单的办法:请质量负责人指出新清单上每一个关键项目背后的条款。如果答案仍然是某一页已经不再单独成立的附录,那么转化工作其实没有做。

延伸阅读

  • 《脑机接口医疗器械:注册路径》(第 454 篇)——新兴器械类别的注册一侧。

来源

  • 国家药监局·关于印发无菌医疗器械等四个检查指导原则的通知:https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjylqx/20261028170125118.html
  • 国家药品监督管理局:https://www.nmpa.gov.cn/
  • 中国政府网:https://www.gov.cn/
  • 国家市场监督管理总局:https://www.samr.gov.cn/

Wholly Foreign-Owned Hospitals in China: The Nine-City Pilot, the Medical Institution Licence and What Stays Closed

  • The permission to set up a Wholly Foreign-Owned Hospital rests on a notice of 7 September 2024 issued by the Ministry of Commerce, the National Health Commission and the National Medical Products Administration, not on any rule issued in 2026.
    允许设立外商独资医院的依据,是商务部、国家卫生健康委、国家药监局 2024 年 9 月 7 日印发的试点通知,而不是 2026 年出台的任何新规。
  • The Nine-City Pilot covers Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and the whole of Hainan Island.
    九地试点包括北京、天津、上海、南京、苏州、福州、广州、深圳和海南全岛。
  • Traditional Chinese Medicine is excluded from the pilot and public hospitals may not be acquired; those are the two hard boundaries of the permission.
    中医类不在试点范围内,也不含并购公立医院——这是这项许可的两条硬边界。
  • The operational plan for the wholly foreign-owned hospital pilot took effect in April 2025 and fixes the pilot areas, access conditions and scope of business a project must satisfy.
    独资医院领域扩大开放试点工作方案于 2025 年 4 月施行,确定了试点地区、准入条件和经营范围等具体要求。
  • A wholly foreign-owned hospital is a medical institution rather than an ordinary foreign-invested company: it needs pre-establishment approval and then a Medical Institution Licence before it can treat a patient.
    外商独资医院是医疗机构,不是普通外商投资企业:须先取得设置批准,再取得《医疗机构执业许可证》,才能接诊。
  • On 22 October 2026 the Ministry of Commerce said it would deepen the opening pilot in wholly foreign-owned hospitals; that is a statement of direction, it adds no city to the list, and any expansion depends on a formal document.
    2026 年 10 月 22 日商务部表示将深化独资医院等领域开放试点;这是方向性表述,并未新增试点地区,是否扩围取决于正式文件。
  • Foreign doctors need their own Practising Registration and imported devices and medicines need registration or filing with the national drug regulator; a hospital licence covers neither.
    外籍医师须另行办理执业注册,进口医疗器械与药品须取得国家药监部门注册或备案;医院执业许可不覆盖这两项。

Wholly Foreign-Owned Hospitals in China: The Nine-City Pilot, the Medical Institution Licence and What Stays Closed | 外商独资医院扩大试点:九地名单、执业许可与尚未开放的部分

Overview

A foreign hospital group looking at China meets two documents, and the order in which it reads them decides whether the project is viable. The first is the negative list for foreign investment, which still treats medical institutions as a restricted sector. The second is the notice of 7 September 2024 issued by the Ministry of Commerce, the National Health Commission and the National Medical Products Administration, which permits wholly foreign-owned hospitals in nine places: Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and the whole of Hainan Island.

In April 2025 the operational plan for the wholly foreign-owned hospital pilot took effect, setting out pilot areas, access conditions and scope of business in working detail. That plan, rather than the 2024 notice, is what a project team should read line by line.

Nothing changed in October 2026. At a State Council Information Office briefing on 22 October 2026, Wu Di of the Ministry of Commerce’s foreign investment administration said the ministry would deepen the opening pilots in cloud computing, biotechnology and wholly foreign-owned hospitals to release service-sector investment potential. That is a statement of direction. It adds no city to the list, and any expansion will arrive through a formal document. On ministry data, services took more than 70 per cent of China’s total actual use of foreign capital in 2025, which is why the sector keeps appearing in opening statements.

What the pilot permits

The permission is narrow. A wholly foreign-owned hospital may be established in one of the nine places to provide medical services other than those in the Traditional Chinese Medicine category, and it must satisfy the access conditions in the operational plan — conditions that run to the investor, the site, the bed scale, the departments and the staffing.

Two features of the design are easy to miss. The permission is place-specific: outside the nine places the negative list position is unchanged, so a group cannot take a licence granted in Shanghai and open a branch in Chengdu on the strength of it. And the permission is for establishment rather than unrestricted operation: the hospital still needs every ordinary licence a medical institution needs, plus the equipment and drug approvals described below.

The scope of business deserves early attention because it drives the investment case: a general hospital, a specialty hospital and a surgical centre meet different requirements on departments, beds and personnel, and provincial rules may add local conditions. Written confirmation of the intended scope, obtained before the feasibility study is signed off, is cheaper than discovering the mismatch at registration.

The two hard boundaries

Traditional Chinese Medicine is excluded. The exclusion is drawn at the level of the TCM category. A project that intends to offer acupuncture, tuina or herbal consultation alongside Western medicine should ask the provincial health commission how the exclusion applies to specific service lines, rather than assume that a TCM department inside a Western-medicine hospital sits outside the rule.

Public hospitals may not be acquired. The boundary is drawn at public hospitals specifically. Greenfield construction is the route the pilot contemplates. Other forms of participation in existing non-public facilities are governed by the operational plan and by provincial rules, and should be put to the authorities as a question rather than treated as settled.

The pilot is in any case an opening inside a restricted sector, not the removal of the restriction, and documents drafted for headquarters should say so.

From setting approval to a licence to practise

A wholly foreign-owned hospital is a medical institution, not an ordinary foreign-invested company, and the sequence reflects that.

The first step is pre-establishment approval — the setting approval required by the regulation on the administration of medical institutions. The application goes to the health authority at the level the operational plan specifies, in practice the provincial level, and carries the substance of the project: a feasibility study, site and floor plans, proposed beds, departments and staffing, funding evidence and the foreign investor’s own qualifications.

The second step is registration, which produces the Medical Institution Licence. The licence records the name, address, legal representative, principal person in charge, permitted diagnostic and treatment subjects and bed count. Treating patients before that licence issues is not a scheduling problem to be managed; it is practice without a licence.

The third step is corporate. The investor’s company is registered under the foreign investment law and files the foreign investment information report. The hospital licence and the company registration are separate instruments held by different authorities, and neither substitutes for the other.

Alongside these sit the permits that follow the building and the equipment: configuration approval for large medical equipment, radiation diagnosis and treatment permits, and environmental and fire acceptance. Together they set the critical path.

Three misconceptions

That wholly-owned means free pricing and free hiring. Non-public medical institutions set service prices under market adjustment rather than government guidance, but a hospital seeking medical insurance designation accepts the payment standards, price publicity and cost-control rules that come with it, and foreign doctors still need their own practising registration. Ownership displaces neither constraint.

That a public hospital can be bought. It cannot, under this pilot; a transaction structured as an acquisition of a public facility will not be approved on the strength of the 2024 notice.

That the model replicates nationally. The permission is confined to the nine places. A multi-city plan needs a multi-city legal analysis, and in most cities the answer today remains a joint venture.

People, devices, medicines and payment

Foreign doctors practising in China need registration of their own. Short-term practice requires a foreign physician short-term practice permit, valid for no more than one year; longer practice requires a Chinese physician qualification and registration. One regional variation is worth knowing: under the trade facilitation measures announced on 29 October 2026 for the Hainan Free Trade Port, the validity of the practising permit for foreign physicians in Hainan extends from one year to three. That is a Hainan-specific arrangement, and it matters when staffing costs for a Hainan site are modelled.

Imported medical devices need registration or filing with the National Medical Products Administration, and large equipment needs configuration approval before installation. Imported medicines need their own registration; the channels for clinically urgent, small-quantity imports are arrangements for specific areas and are not part of this pilot.

On payment, medical insurance designation is applied for locally and is not automatic. Most wholly foreign-owned hospitals in the pilot will run a mixed model: self-pay and commercial insurance direct billing for the core business, designation where local rules and the case allow it.

Research involving human genetic resources requires separate approval for collection, preservation and international cooperation.

Practical steps

  • Choose the city first, then read that city’s implementing rules. The nine places do not implement identically.
  • Open a pre-application channel with the provincial health commission and obtain written confirmation of the intended scope, bed scale and department list.
  • Have the foreign investor’s qualification documents notarised and authenticated, with Chinese translations in the format the receiving authority expects.
  • Sequence device registrations and physician registrations against the planned opening date; registration timelines, not construction, usually set the critical path.
  • Confirm with the commerce department that the project falls inside the pilot, and keep that confirmation with the file supporting the foreign investment information report.
  • Discuss insurance designation with the local medical insurance bureau early, because the answer shapes the revenue model rather than merely the billing process.

Outlook

The direction of travel is towards more service-sector opening, and hospitals are named in that direction. The operative question is not what the next statement will say but which document grants the permission and where it applies. Until a formal expansion is published, the nine places are the perimeter.

Related reading

  • *Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening* (Article 227) — the earlier framing of the pilot within private healthcare policy.
  • *Pharma and biotech opening moves from the foreign-investment action plan* (Article 405) — where the biotechnology pilot sits relative to hospitals.

Sources

  • 商务部、国家卫生健康委、国家药监局·关于在医疗领域开展扩大开放试点工作的通知(2024-09-07):https://www.mofcom.gov.cn/
  • 国务院新闻办公室·”十五五”商务高质量发展有关情况新闻发布会(2026-10-22):https://www.scio.gov.cn/live/2026/39833/index.html
  • 中国政府网·国务院政策文件库:https://www.gov.cn/
  • 国家卫生健康委员会·医疗机构管理条例及配套规章:https://www.nhc.gov.cn/
  • 国家药品监督管理局·医疗器械注册与备案管理:https://www.nmpa.gov.cn/

外商独资医院扩大试点:九地名单、执业许可与尚未开放的部分

概述

一家境外医院集团看中国市场,会遇到两份文件,而阅读顺序决定了项目是否可行。第一份是外商投资准入负面清单,其中医疗机构仍属限制类。第二份是商务部、国家卫生健康委、国家药监局 2024 年 9 月 7 日印发的试点通知,允许在北京、天津、上海、南京、苏州、福州、广州、深圳和海南全岛设立外商独资医院。

2025 年 4 月,《独资医院领域扩大开放试点工作方案》施行,把试点地区、准入条件和经营范围落到操作层面。项目团队应当逐条研读的是这份工作方案,而不是 2024 年的通知本身。

2026 年 10 月没有新变化。2026 年 10 月 22 日,在国务院新闻办公室发布会上,商务部外国投资管理司负责人吴迪表示,将深化云计算、生物技术、独资医院等领域开放试点,释放服务业引资潜力。这是方向性表述:它没有为名单增加任何一个城市,是否扩围要看正式文件。按商务部数据,2025 年服务业占全国实际使用外资总额比重超过七成,这也是服务业反复出现在开放表述中的原因。

试点允许什么

许可范围很窄。外商独资医院可以设在九地之一,提供中医类以外的医疗服务,并且必须满足工作方案中的准入条件——这些条件涉及投资主体、选址、床位规模、科室设置和人员配备。

这项设计有两点容易被忽略。其一,许可与地点绑定:九地之外,负面清单的立场没有变化,企业不能拿着一张在上海取得的许可去成都开分院。其二,这是设立环节的许可,不是无限制经营:医院仍须取得任何医疗机构都需要的全部许可,还要取得下文所述的设备与药品审批。

经营范围应当尽早确定,因为它决定投资测算:综合医院、专科医院与外科中心,在科室、床位和人员上的要求并不相同,省级规则还可能附加本地条件。在可行性研究定稿之前取得关于拟设范围的书面确认,比在登记环节才发现不匹配要便宜得多。

两条硬边界

中医类除外。 排除是在中医类这一类别层面作出的。如果项目打算在综合医疗之外提供针灸、推拿或中医门诊,应当向省级卫生健康部门询问该排除对具体诊疗科目如何适用,而不是自行推定”西医院里的中医科不受限制”。

不含并购公立医院。 边界明确划在公立医院上。试点设想的路径是新建。对现有非公立医疗机构的其他参与方式,由工作方案和省级规则调整,宜作为问题向主管部门提出,而不宜当作已有定论。

还需说明一点:试点是在限制类行业内部开的口子,不是取消限制;写给总部的材料应当把这一点写清楚。

从设置批准到执业许可

外商独资医院是医疗机构,不是普通外商投资企业,办理顺序也体现了这一点。

第一步是设置审批,即《医疗机构管理条例》体系下的设置批准。申请提交至工作方案确定的层级,实践中为省级卫生健康行政部门,材料承载的是项目的实质内容:可行性研究报告、选址与建筑设计平面图、拟设床位、科室与人员、资金证明,以及外方投资者自身的资质文件。

第二步是执业登记,产出《医疗机构执业许可证》。许可证载明名称、地址、法定代表人、主要负责人、诊疗科目和床位。在许可证下发前接诊,不是可以排期的进度问题,而是无证执业。

第三步是主体层面。投资者的公司依外商投资法登记,并报送外商投资信息报告。医院执业许可与公司登记是两份由不同机关出具的文书,彼此不能替代。

与上述三步并行的,是跟着建筑和设备走的许可:大型医用设备配置许可、放射诊疗许可,以及环保与消防验收。这些合起来决定了关键路径。

三个误区

以为”独资”等于自由定价、自由引医。 非公立医疗机构的医疗服务价格实行市场调节价,不由政府定价;但一家希望取得医保定点的医院,要接受随之而来的支付标准、价格公示和费用控制要求,外籍医师也仍须办理各自的执业注册。股权结构改变不了这两项约束。

以为可以收购公立医院。 本试点下不可以。把交易结构设计成收购公立医疗机构,不能凭 2024 年的通知获得批准。

以为模式可以全国复制。 许可限于九地。多城市布局需要多城市的法律分析,而在多数城市,目前的答案仍是合资。

人员、设备、药品与支付

外籍医师在华执业须另行办理注册。短期行医需取得外国医师短期行医许可,有效期不超过一年;长期执业须取得中国医师资格并注册。有一处地区差异值得了解:按 2026 年 10 月 29 日公布的海南自由贸易港贸易便利化措施,外籍医师在海南的执业许可有效期由一年延长至三年。这是海南特有的安排,在测算海南机构人力成本时会用到。

进口医疗器械须取得国家药品监督管理局的注册或备案,大型设备在装机前须取得配置许可。进口药品须另行注册;临床急需少量进口的通道属于特定区域的安排,不在本试点范围内。

支付方面,医保定点在属地申请,并非自动取得。试点内的外商独资医院多数会走混合模式:核心业务以自费与商业保险直付为主,在本地规则和具体条件允许时申请定点。

涉及人类遗传资源的科研,其采集、保藏和对外合作须另行取得审批。

实务动作

  • 先定城市,再读该市的实施细则。九地的执行并不一致。
  • 与省级卫生健康部门建立预沟通渠道,取得关于拟设范围、床位规模和科室清单的书面确认。
  • 外方资质文件办理公证认证,中文译本按受理机关的格式准备。
  • 把器械注册与医师注册排到计划开业日之前倒推。决定关键路径的通常是注册周期,而不是施工。
  • 向商务主管部门确认项目属于试点范围,并将该确认与支持外商投资信息报告的材料一并归档。
  • 尽早与属地医保部门沟通定点事宜,因为这个答案决定的是收入模型,而不只是结算流程。

展望

方向是服务业进一步开放,医院被写进了这个方向。对具体项目而言,真正的问题不是下一句表态会说什么,而是哪份文件授予许可、许可适用于哪里。在正式扩围文件公布之前,九地就是边界。

延伸阅读

  • 《外资独资医院试点与社会办医扩大开放》(第 227 篇)——试点在社会办医政策中的早期定位。
  • 《外资行动方案中的医药与生物技术开放举措》(第 405 篇)——生物技术试点与医院试点的相对位置。

来源

  • 商务部、国家卫生健康委、国家药监局·关于在医疗领域开展扩大开放试点工作的通知(2024-09-07):https://www.mofcom.gov.cn/
  • 国务院新闻办公室·”十五五”商务高质量发展有关情况新闻发布会(2026-10-22):https://www.scio.gov.cn/live/2026/39833/index.html
  • 中国政府网·国务院政策文件库:https://www.gov.cn/
  • 国家卫生健康委员会·医疗机构管理条例及配套规章:https://www.nhc.gov.cn/
  • 国家药品监督管理局·医疗器械注册与备案管理:https://www.nmpa.gov.cn/

Brain-computer interface medical devices: China’s innovative registration policy direction

  • At the 2026 International Biomedical Industry Innovation Beijing Forum in Yizhuang, an official from the NMPA Medical Device Registration Management Department said brain-computer interface (BCI) has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is positioned as a future industry.
    在2026国际生物医药产业创新北京论坛(北京亦庄)”神经调控与脑机接口技术产业发展论坛”上,国家药监局医疗器械注册管理司相关负责人表示,脑机接口已被纳入我国”十五五”规划、写入政府工作报告,明确作为未来产业予以布局。
  • The regulator signalled that supporting innovative registration and management policies will be introduced to systematically support the development and translation of BCI medical devices.
    药监部门表示将配套创新注册管理政策,系统支持脑机接口医疗器械的研发与落地转化。
  • As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings; in 2025 the NMPA approved 14,187 medical-device registrations, up 8 per cent year on year.
    截至2026年7月底,全国有效医疗器械注册备案产品超过34.7万件;2025年国家药监局共批准医疗器械注册14187项,同比增长8%。
  • The “Spring Rain Action” clinical-translation programme has collected more than 400 Class III medical-device products and placed 22 quality projects into an expedited pre-review green channel.
    医疗器械临床创新成果转化”春雨行动”已征集400多个三类医疗器械产品,已有22个优质项目纳入审评前置绿色通道。
  • On standards, three industry standards for BCI have been issued, ten national standards and three industry standards are under development, and one international-standard proposal has been submitted, covering EEG acquisition, signal transmission, motor-intention decoding and device reliability.
    在标准方面,脑机接口领域已累计发布3项行业标准,立项10项国家标准、3项行业标准,并提交1项国际标准立项提案,覆盖脑电采集、信号传输、运动意图解码与设备可靠性等核心技术环节。
  • The regulator describes its approach as “front-loading regulation and standards first”, including pre-application technical guidance for both invasive and non-invasive products and unified naming and classification rules.
    监管方式被概括为”监管前置、标准先行”,包括对多款侵入式、非侵入式产品开展前置技术指导,并统一产品命名与分类界定规则。
  • For foreign companies the practical relevance is analytical rather than a formal commitment: the policy direction points to clearer registration pathways, but no specific BCI approval timelines, acceptance numbers or product names have been published.
    对境外企业而言,其实际意义属分析性判断而非官方承诺:政策方向指向更清晰的注册路径,但截至目前并未公布具体的脑机接口审批时限、受理编号或产品名称。

Brain-computer interface medical devices: China’s innovative registration policy direction | 脑机接口医疗器械:中国创新注册管理政策方向

Overview

In October 2026, the 2026 International Biomedical Industry Innovation Beijing Forum was held in Yizhuang, Beijing. At the forum’s “Neuromodulation and Brain-Computer Interface Technology Industry Development Forum”, an official from the Medical Device Registration Management Department of the National Medical Products Administration (NMPA) set out the regulator’s current reading of brain-computer interface (BCI) medical devices and the registration policy direction attached to them.

According to the remarks, BCI has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is expressly positioned as a future industry. On that basis, the regulator said it would put in place supporting innovative registration and management policies to systematically support the research, development and translation of BCI medical devices.

The remarks are a policy-direction statement rather than a new rule. They describe how the existing medical-device registration system is being oriented towards BCI, and they rest on a set of published industry figures that show how the registration base and the innovation-support toolkit have grown.

Key developments

The official’s remarks combined a positioning statement with concrete numbers on China’s medical-device registration landscape.

  • Registration base. As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings, spanning Class III registration certificates, Class II registration certificates and Class I filings.
  • Annual approvals. In 2025, the NMPA approved 14,187 medical-device registrations, an increase of 8 per cent year on year.
  • Clinical translation programme. The “Spring Rain Action” for the translation of clinical innovations in medical devices had collected more than 400 Class III medical-device products, covering high-end tracks such as BCI, interventional surgical robots, AI diagnostic software and high-end interventional implants and biomaterials. 22 quality projects had been placed into an expedited pre-review green channel.

Read together, these figures describe a large and still-growing registration pipeline, and a deliberate effort to move selected high-end products through review faster than the ordinary queue.

Standards first: the pre-review and standards toolkit

Alongside the registration figures, the remarks described the regulator’s operating approach as “front-loading regulation and standards first”.

On standards, the BCI field has seen:

  • three industry standards issued;
  • ten national standards and three industry standards initiated (立项); and
  • one international-standard proposal submitted.

The published standards cover core technical links including EEG acquisition, signal transmission, motor-intention decoding and device reliability.

On regulation, the approach includes:

  • advance planning of regulatory-science research;
  • pre-application technical guidance for a number of both invasive and non-invasive products; and
  • unified rules for product naming and classification.

The “standards first” logic matters for a technology like BCI, where the boundary between a medical device, a consumer wearable and a research instrument can be genuinely unclear. Naming and classification rules, and the existence of standards for core components, are the practical preconditions for a device to move into a defined registration pathway.

Next steps in regulation

The official set out the next steps in general terms: continuing to deepen reform of the medical-device review and approval system and to increase support for high-end innovative devices. Specific measures mentioned included:

  • optimising the review mechanism for “globally new” products;
  • providing front-loaded services such as clinical-trial pre-review and technical consultation; and
  • thereby accelerating the market launch of landmark products.

These are direction statements. They indicate where the regulator intends to concentrate facilitation effort, not the terms on which any individual product will be reviewed.

Practical implications for foreign companies

The following points are analytical observations, not official commitments. They describe what the policy direction may mean for foreign BCI and neurotechnology companies considering the China market.

  • The direction of travel is clearer, the details are not. A stated intent to build supporting innovative registration policies for BCI signals that the regulator is treating the field as a priority. It does not, on its own, change any filing requirement, and no BCI-specific approval timeline, acceptance number or product name has been published.
  • Classification and naming are the first practical questions. Because the regulator is unifying naming and classification rules for BCI, a company’s early task is to understand how its product would be classified and named under the Chinese system, since that determines the registration pathway.
  • Standards participation is a defined channel. With national and industry standards under development and an international-standard proposal submitted, there is an active standards-setting process. Foreign companies commonly monitor or participate in such processes through their China entities or industry associations, though the terms of participation follow the applicable standards rules.
  • Patent and intellectual-property positioning deserves early attention. BCI spans hardware, signal-processing algorithms and software. Companies usually review how their patent portfolio maps onto the Chinese classification and standards landscape before committing to a registration strategy. This is a commercial and legal planning point, not a statement of any regulatory preference.
  • Translation programmes are a signal, not a guarantee. The “Spring Rain Action” pipeline shows that a subset of high-end products is being routed into an expedited pre-review channel. Being in a high-priority field is relevant context, but selection for such programmes is a separate process.

Related considerations

For a foreign company, the sensible reading of these remarks is as a map of the regulator’s priorities rather than a set of entitlements. The registration figures show scale; the standards activity shows the field maturing towards defined technical requirements; and the “front-loading” language shows where facilitation effort is being directed. A company planning a China BCI strategy would typically combine this policy context with a product-specific review of classification, standards alignment, patent position and the appropriate registration pathway, and would confirm current requirements against the latest official publications before relying on any particular route.

Sources

  • 经济参考报 2026-10-08 报道(环球医药网转载)— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
  • 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
  • 中国网(受权发布)— 《关于发展新质生产力的意见》全文(含”前瞻布局未来产业”等产业定位表述): https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml

脑机接口医疗器械:中国创新注册管理政策方向

概述

2026年10月,2026国际生物医药产业创新北京论坛在北京亦庄举行。在该论坛的”神经调控与脑机接口技术产业发展论坛”上,国家药品监督管理局医疗器械注册管理司相关负责人就脑机接口医疗器械的监管现状与注册政策方向作了介绍。

据该负责人介绍,脑机接口已被纳入我国“十五五”规划、写入政府工作报告,明确作为未来产业予以布局。在此基础上,药监部门表示将配套创新注册管理政策,系统支持脑机接口医疗器械的研发与落地转化。

上述表态属政策方向性说明,而非新出台的规则。它描述的是现行医疗器械注册体系正如何向脑机接口领域倾斜,并以一组已公布的行业数据为依托,展示注册基数与创新支持工具的发展情况。

主要进展

该负责人的介绍将产业定位与具体数据结合在一起,勾勒出我国医疗器械注册的整体面貌。

  • 注册基数。 截至2026年7月底,全国有效医疗器械注册备案产品超过34.7万件,涵盖三类注册证、二类注册证及一类备案产品。
  • 年度批准量。 2025年,国家药监局共批准医疗器械注册14187项,同比增长8%。
  • 临床转化项目。 医疗器械临床创新成果转化“春雨行动”已征集400多个三类医疗器械产品,覆盖脑机接口、介入手术机器人、人工智能诊疗软件、高端植介入生物材料等高端赛道;已有22个优质项目纳入审评前置绿色通道。

综合来看,这组数据一方面说明注册管线规模庞大且仍在增长,另一方面也说明监管机构有意让部分高端产品以快于常规队列的方式通过审评。

标准先行:前置审评与标准工具箱

在注册数据之外,该负责人将监管机构的运行思路概括为“监管前置、标准先行”。

在标准方面,脑机接口领域已实现:

  • 累计发布3项行业标准;
  • 立项10项国家标准、3项行业标准;
  • 提交1项国际标准立项提案。

已发布的标准覆盖脑电采集、信号传输、运动意图解码、设备可靠性等核心技术环节。

在监管方面,相关做法包括:

  • 提前布局监管科学研究;
  • 对多款侵入式、非侵入式产品开展前置技术指导;
  • 统一产品命名与分类界定规则。

“标准先行”的逻辑对脑机接口这类技术尤为重要——医疗器械、消费级可穿戴设备与研究仪器之间的边界有时并不清晰。命名与分类界定规则,以及核心部件标准的建立,是产品得以进入明确注册路径的现实前提。

下一步监管方向

该负责人以总体表述方式提出了下一步方向:持续深化医疗器械审评审批制度改革,持续加大高端创新器械扶持力度。其中提到的具体举措包括:

  • 优化”全球新”产品审评机制;
  • 提供临床试验预审、技术咨询等前置服务;
  • 进而加速标杆产品上市。

这些属方向性表述,指示监管机构拟在何处集中便利化资源,并不等同于任何单一产品的审评条件。

对境外企业的实务意义

以下要点为分析性观察,并非官方承诺。它们描述的是该政策方向对考虑进入中国市场的境外脑机接口与神经技术企业可能意味着什么。

  • 方向更清晰,细节尚未明确。 表态提出将为脑机接口构建配套创新注册政策,说明监管机构将该领域视为优先方向。但这一表态本身并不改变任何申报要求,且截至目前并未公布脑机接口专属的审批时限、受理编号或产品名称。
  • 分类与命名是首要实务问题。 由于监管机构正在统一脑机接口的命名与分类界定规则,企业的早期工作之一是弄清其产品在中国体系下将被如何分类与命名,因为这决定了注册路径。
  • 参与标准化是一条既有通道。 随着国家标准与行业标准在研、国际标准提案已提交,标准化进程处于活跃状态。境外企业通常通过其在华主体或行业协会关注或参与此类进程,但参与条件须遵循适用的标准化管理规定。
  • 专利与知识产权布局宜及早关注。 脑机接口横跨硬件、信号处理算法与软件。企业通常会在确定注册策略前,先梳理其专利组合如何对应中国的分类与标准格局。这属商业与法律规划事项,并非监管倾向性表述。
  • 转化项目是信号,而非保证。 “春雨行动”管线显示,部分高端产品正被纳入审评前置快速通道。身处高优先级领域是相关背景,但能否入选此类项目是另一套独立程序。

相关考量

对境外企业而言,将上述表态理解为监管机构优先事项的路线图,比理解为一系列既得权益更为妥当。注册数据体现规模,标准化活动体现该领域正走向明确的技术要求,”前置”表述则体现便利化资源投入的方向。规划中国脑机接口战略的企业,通常会将这一政策背景与针对具体产品的分类、标准对齐、专利布局及相应注册路径评估结合起来,并在依赖任何具体路径前,依据最新官方发布确认现行要求。

来源

  • 经济参考报 2026-10-08 报道(环球医药网转载)— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
  • 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
  • 中国网(受权发布)— 《关于发展新质生产力的意见》全文(含”前瞻布局未来产业”等产业定位表述): https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml

Traditional Chinese Medicine Knowledge Protection: What the September 2026 Draft Regulation Means for Foreign Pharmaceutical and Healthcare Companies

  • On 18 September 2026, the State Council executive meeting reviewed and approved in principle the Draft Regulation on the Protection of Traditional Chinese Medicine Knowledge, describing traditional Chinese medicine theory, techniques and formulas as important resources for China’s own innovation and calling for comprehensive strengthening of protection and management.
    2026年9月18日,国务院常务会议审议通过《中医药传统知识保护条例(草案)》,会议指出中医药理论、技术和方药是我国自主创新的重要资源,要全面加强保护管理。
  • The regulation is to establish a protection system for traditional Chinese medicine knowledge: after registration and review-based recognition, a holder enjoys rights to indicate identity, to transmit and use, to informed consent, to benefit sharing, to integrity protection and to require disclosure of source, while medical institutions are encouraged to proactively investigate and develop proven formulas, secret formulas and techniques.
    条例将建立中医药传统知识保护制度:经登记并审核认定后,持有人享有表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源等权利,并鼓励医疗机构主动调查发现中医药验方、秘方和技法并进行开发研究。
  • The draft has not been published in full, so no article numbers, effective date, registration procedure or recognition thresholds are available; planning should rest on the official record as it appears.
    草案尚未公布全文,条款编号、生效日期、登记程序与认定门槛均无从确认;相关规划应以官方后续发布为准。
  • The IP Protection and Application 15th Five-Year Plan (State Council document No. 30 of 2026, issued on 27 July 2026) already lists “issuing the Regulation on the Protection of Traditional Chinese Medicine Knowledge” and strengthening access and benefit-sharing systems for traditional knowledge and folk literature and art.
    《知识产权保护和运用”十五五”规划》(国发〔2026〕30号,国务院2026年7月27日印发)已明确”出台中医药传统知识保护条例”,并加强传统知识、民间文艺等获取和惠益分享制度建设。
  • The same Plan directs improvement of intellectual property protection rules for algorithms and AI-generated output and exploration of data intellectual property protection rules, matters relevant to digital health and AI-assisted research.
    同一规划还提出完善算法、人工智能生成物等知识产权保护规则,探索构建数据知识产权保护规则,与数字健康及人工智能辅助研究密切相关。
  • The revised Trademark Law was adopted on 26 June 2026 and takes effect on 1 January 2027; it writes the principle of good faith into the law and targets bad-faith filings, trademark hoarding and agency conduct.
    新修订《商标法》于2026年6月26日通过、2027年1月1日施行,将诚实信用原则写入法律,并针对恶意抢注、商标囤积及代理行为作出规范。

Traditional Chinese Medicine Knowledge Protection: What the September 2026 Draft Regulation Means for Foreign Pharmaceutical and Healthcare Companies | 中医药传统知识保护:2026年9月国务院常务会议审议通过条例草案对外资医药与大健康企业的意义

Overview

On 18 September 2026, the State Council executive meeting reviewed and approved in principle the Draft Regulation on the Protection of Traditional Chinese Medicine Knowledge. In the official account, traditional Chinese medicine theory, techniques and formulas are described as important resources for China’s own innovation, and the requirement is to comprehensively strengthen their protection and management. The draft has not yet been published in full.

For foreign pharmaceutical, healthcare and wellness companies working in or with China, the development matters for a practical reason. It sits alongside a wider set of intellectual property measures that took effect or moved through the system in 2026, from the revised Trademark Law to the IP Protection and Application 15th Five-Year Plan. Together they shape how traditional knowledge, research collaboration and brand assets are documented and defended.

This article sets out the official wording, the protection system as described, the institutional arrangements in the 15th Five-Year Plan, and the practical points foreign companies may wish to consider. It deliberately does not speculate beyond the official record.

The September 2026 decision

The executive meeting approved the draft and set the direction of policy. Traditional Chinese medicine theory, techniques and formulas are treated as important resources for China’s own innovation, and the task set is to comprehensively strengthen protection and management.

The regulation is to establish a protection system for traditional Chinese medicine knowledge. Under that system, after registration and review-based recognition, a holder enjoys a set of rights: to indicate identity, to transmit and use the knowledge, to give informed consent, to share in benefits, to integrity protection, and to require disclosure of source.

The official account also encourages medical institutions to proactively investigate and discover traditional Chinese medicine proven formulas, secret formulas and techniques, and to carry out development and research on them.

Because the full text has not been published, no article numbers, effective date, registration procedure or definitional thresholds are available. Companies should treat any such details as pending until an official release appears, and should not rely on descriptions that circulate without an official source.

What the 15th Five-Year Plan already provides

The draft regulation is not an isolated initiative. The IP Protection and Application 15th Five-Year Plan (State Council document No. 30 of 2026, issued on 27 July 2026) had already placed it within a wider programme.

The Plan calls for accelerating improvement of the patent-related legal system, for comprehensively revising the Trademark Law and its implementing regulations, and for issuing the Regulation on the Protection of Traditional Chinese Medicine Knowledge. It also directs strengthening access and benefit-sharing systems for traditional knowledge, folk literature and art, and improving intellectual property protection rules for algorithms and AI-generated output as well as for platform-economy development. It further calls for exploring data intellectual property protection rules.

The Plan sets out milestones. By 2030, China’s comprehensive intellectual property strength and international competitiveness are to be further enhanced, with decisive progress in building an intellectual property power. Looking to 2035, comprehensive intellectual property competitiveness is to rank among the world’s leading.

For a company mapping its China research and brand strategy, the Plan is useful because it shows the direction of travel across several instruments at once rather than the detail of a single new rule.

Adjacent intellectual property developments in 2026

A nationwide briefing tour on new intellectual property rules began in Jinan on 20 September 2026, covering the Shandong and Anhui region. The briefings addressed three instruments.

The revised Trademark Law writes the principle of good faith into the law, targets bad-faith filings and the hoarding of trademarks, tightens supervision of trademark agencies and strengthens industry credit constraints. It was adopted on 26 June 2026 and takes effect on 1 January 2027.

The revised Regulation on the Protection of Layout Designs of Integrated Circuits brings layout designs performing functions such as integrated photonics and quantum into the statutory scope of protection and establishes an originality declaration system.

The revised Measures for the Prioritised Examination of Patents steer prioritised examination resources toward emerging industries and key core technology programmes, and establish a central-local coordination mechanism.

Read together with the traditional knowledge regulation, these measures point in a consistent direction: more explicit documentation of what is claimed, who holds it and where it came from.

Practical implications for foreign pharmaceutical and healthcare companies

Due diligence on traditional knowledge. Where a project touches formulas, techniques or sources of traditional knowledge, the rights described in the official account — identity, transmission and use, informed consent, benefit sharing, integrity protection and disclosure of source — suggest that provenance and consent questions may become part of the record. Companies may wish to document how a formula or technique was obtained and on what terms.

Collaboration agreements. Research with hospitals, institutes and practitioners should be documented, with clarity on background and foreground rights, on publication, and on how jointly created results are handled.

Patent and brand layout. The Plan’s direction on patents and the revised Trademark Law both reward early, well-documented filing strategies. A portfolio that depends on distinctive names and marks should be checked against the good-faith and bad-faith filing provisions as they take effect.

Digital and AI-related work. The Plan’s references to algorithms, AI-generated output and data intellectual property are relevant to digital health, AI-assisted screening and data-driven research, where ownership of outputs and datasets is often unsettled.

Watch the official record. Because the draft regulation is not yet published in full, the specific registration route, recognition criteria and benefit-sharing mechanics remain to be seen. Planning should be revisited when the text and any supporting measures are released.

Related considerations

Foreign-invested companies in the healthcare and wellness sectors already work within sector-specific rules on drugs, devices, healthcare services and advertising. The traditional knowledge regulation adds a knowledge-protection layer rather than replacing those rules. Keeping the two layers distinct — what may be made and sold, and what knowledge may be used and on what terms — helps avoid conflating a licensing question with a market-access question.

Sources

  • 国家知识产权局(《知识产权保护和运用”十五五”规划》专栏): https://www.cnipa.gov.cn/col/col3692/index.html
  • 酒泉市公安局(《知识产权保护和运用”十五五”规划》国发〔2026〕30号全文转载): https://gaj.jiuquan.gov.cn/gaj/c106483/202609/856895252998428d9990e67d9af39108.shtml
  • 国家知识产权局(官网,9月工作动态): https://www.cnipa.gov.cn/?filter=0
  • 大众网滨州(知识产权新规全国巡回宣贯,9月20日济南,9-23): https://www.toutiao.com/article/7688564714451780098/
  • 中国政府网: https://www.gov.cn/

中医药传统知识保护:2026年9月国务院常务会议审议通过条例草案对外资医药与大健康企业的意义

概述

2026年9月18日,国务院常务会议审议通过《中医药传统知识保护条例(草案)》。官方表述指出,中医药理论、技术和方药是我国自主创新的重要资源,要全面加强保护管理。该草案尚未公布全文。

对在华开展业务或与中国合作的外资医药、医疗健康与大健康企业而言,这一进展具有现实意义:它与2026年已经施行或正在推进的一揽子知识产权举措并列,从新修订《商标法》到《知识产权保护和运用”十五五”规划》,共同影响传统知识、研究协作与品牌资产的记录与维护方式。

本文梳理官方原文表述、条例拟确立的保护制度、规划中的制度安排,以及外资企业可能关注的实务要点,并刻意不作出超出官方记录范围的推断。

2026年9月的决定

国务院常务会议审议通过草案并确定了政策方向。中医药理论、技术和方药被视为我国自主创新的重要资源,任务要求是全面加强保护管理。

条例将建立中医药传统知识保护制度。在该制度下,经登记并审核认定后,持有人享有一组权利:表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源。

官方表述还鼓励医疗机构主动调查发现中医药验方、秘方和技法,并进行开发研究。

由于全文尚未公布,条款编号、生效日期、登记程序与认定门槛均无从确认。企业宜将此类细节视为待定,直至官方发布为止,不应依赖没有官方出处的描述。

“十五五”规划已作出的安排

该条例草案并非孤立举措。《知识产权保护和运用”十五五”规划》(国发〔2026〕30号,国务院2026年7月27日印发)已把它纳入更宏大的部署。

规划提出加快完善专利相关法律制度,推动商标法及其实施条例全面修改,并出台中医药传统知识保护条例。规划还提出加强传统知识、民间文艺等获取和惠益分享制度建设,完善算法、人工智能生成物以及与平台经济发展相关的知识产权保护规则,并探索构建数据知识产权保护规则。

规划设定了节点目标:到2030年,知识产权综合实力和国际竞争力进一步增强,知识产权强国建设取得决定性进展;展望2035年,知识产权综合竞争力跻身世界前列。

对正在规划中国研究与品牌战略的企业而言,该规划的价值在于,它一次性展示了多项制度工具的共同走向,而不只是一条新规的细节。

2026年相邻的知识产权进展

2026年9月20日,知识产权新规全国巡回宣贯在济南启动,覆盖山东、安徽片区。宣贯围绕三件法规展开。

新修订《商标法》将诚实信用原则写入法律,遏制恶意抢注、囤积商标,严格商标代理监管,强化行业信用约束。该法于2026年6月26日通过,2027年1月1日施行。

新修订《集成电路布图设计保护条例》将集成光子、量子等功能的集成电路布图设计纳入法定保护范围,并建立独创性声明制度。

修订后的《专利优先审查管理办法》使优先审查资源向新兴产业、关键核心技术攻关倾斜,并建立央地协同机制。

与中医药传统知识保护条例合并来看,这些举措指向一个一致的方向:对主张什么、由谁持有、来自何处作出更明确的记录。

对外资医药与大健康企业的实务影响

传统知识尽职调查。 当项目涉及方药、技法或传统知识来源时,官方表述中的权利——表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源——提示来源与同意问题可能进入记录范围。企业宜留存取得方药或技法的途径与条件的书面材料。

合作协议。 与医院、科研院所及从业者的研究合作应有书面安排,就背景权利与前景权利、发表,以及共同形成成果的处理作出清晰约定。

专利与品牌布局。 规划在专利方面的方向与新修订《商标法》都倾向于奖励尽早且记录充分的申请策略。依赖独特名称与标识的资产组合,宜在新法施行后比照诚实信用与恶意申请相关条款作一次核对。

数字与人工智能相关工作。 规划中关于算法、人工智能生成物与数据知识产权的表述,与数字健康、人工智能辅助筛查及数据驱动研究相关,而这些领域中成果与数据集的归属往往并不确定。

关注官方记录。 由于条例草案尚未公布全文,具体登记路径、认定标准与惠益分享机制仍有待观察。待文本及配套办法发布后,宜重新审视既有规划。

相关考虑

医药与大健康领域的外商投资企业,本就需遵循药品、器械、医疗服务与广告等分行业规则。中医药传统知识保护条例增加的是一个知识保护层面,而非取代上述规则。把两个层面区分开来——可以制造与销售什么,以及可以何种条件使用何种知识——有助于避免把许可问题与市场准入问题混为一谈。

来源

  • 国家知识产权局(《知识产权保护和运用”十五五”规划》专栏):https://www.cnipa.gov.cn/col/col3692/index.html
  • 酒泉市公安局(《知识产权保护和运用”十五五”规划》国发〔2026〕30号全文转载):https://gaj.jiuquan.gov.cn/gaj/c106483/202609/856895252998428d9990e67d9af39108.shtml
  • 国家知识产权局(官网,9月工作动态):https://www.cnipa.gov.cn/?filter=0
  • 大众网滨州(知识产权新规全国巡回宣贯,9月20日济南,9-23):https://www.toutiao.com/article/7688564714451780098/
  • 中国政府网:https://www.gov.cn/

Pharma and biotech opening moves from the foreign-investment action plan: segmented production, pilot expansion and the payment chain

  • The Action Plan for Stabilising and Optimising the Utilisation of Foreign Investment (商资发〔2026〕97号, issued 16 June 2026 by MOFCOM, NDRC and MOF) commits the government to “expedite the study and issuance of implementation rules for segmented pharmaceutical production”, easing cross-border segmented manufacturing of biologics and chemical drugs by foreign marketing-authorisation holders.
    商务部、国家发展改革委、财政部《利用外资固稳促优行动方案》(商资发〔2026〕97号,2026年6月16日印发)明确”抓紧研究出台药品分段生产实施细则”,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。
  • The same plan moves to widen pilot geography: authorities will “expedite research and approval to further expand the pilot regions for biotechnology and wholly foreign-owned hospitals” — the two most-watched restricted-service openings of the current cycle.
    同一方案还推动试点扩围:”抓紧研究报批进一步扩大生物技术、外商独资医院领域开放试点区域范围”——这是本轮最受关注的两项限制性服务业开放。
  • The statutory base is already in place: the revised Drug Administration Law Implementation Regulations (published January 2026) turned segmented production from pilot into institution, letting marketing-authorisation holders commission qualified producers to segment-manufacture innovative drugs and clinically urgent drugs when genuinely needed, under a unified quality-assurance system covering all sites.
    法定底座已经就位:修订后的《药品管理法实施条例》(2026年1月公布)把分段生产从试点推向制度——药品上市许可持有人确有需要的,可委托符合条件的企业分段生产创新药、临床急需药品等,并建立覆盖全部生产场地的统一质量保证体系。
  • Commercial proof-of-concept has landed: in May 2026 Johnson & Johnson’s niccalimab injection became the first imported biologic to run domestic segmented production of drug substance in China, with the substance made by WuXi Bio in Wuxi and fill-finish completed in Germany.
    商业验证已经落地:2026年5月,强生制药的尼卡利单抗注射液成为全国首个开展原液境内分段生产的进口生物制品——原液由无锡药明生物生产,制剂在德国完成。
  • Biotech opening pilots are producing registrable outcomes: under the 2024 pilot allowing FIEs to develop and apply human stem-cell and gene diagnosis and therapy technologies in designated free trade zones, at least six foreign companies — including Merck, JW Therapeutics-related entities, Frontera Therapeutics and StarCellBio — have completed registration changes or new filings.
    生物技术开放试点已产出可登记成果:在2024年允许外商投资企业于指定自贸区开展人体干细胞、基因诊断与治疗技术开发应用的试点下,至少6家外资企业(含默克、药明巨诺相关主体、芳拓生物、星奕昂等)已完成经营范围变更或新设登记。
  • Payment and channel measures complete the chain: the plan supports insurers in covering more innovative drugs and devices under commercial health insurance, and calls for an industry collaboration platform to smooth foreign-made pharmaceuticals into retail channels — the “last mile” that has capped foreign pharma revenue in China.
    支付与渠道措施补齐链条:方案支持保险公司将更多创新药械纳入商业保险保障范围,并搭建行业协作平台便利外资企业生产的药品进入零售渠道——这正是此前封顶外资药企中国收入的”最后一公里”。

Pharma and biotech opening moves from the foreign-investment action plan: segmented production, pilot expansion and the payment chain | 外资行动方案中的医药开放组合:分段生产、试点扩围与支付渠道

Overview

The Action Plan for Stabilising and Optimising the Utilisation of Foreign Investment (《利用外资固稳促优行动方案》, 商资发〔2026〕97号), issued on 16 June 2026 by the Ministry of Commerce, the National Development and Reform Commission and the Ministry of Finance with State Council consent, devotes one of its fifteen measures to pharmaceuticals. The measure assembles a “production — marketing-authorisation — payment — channel” package for foreign pharmaceutical and biotech companies: segmented production implementation rules, expanded pilot geography for biotechnology and wholly foreign-owned hospitals, commercial-insurance payment support, and retail-channel facilitation.

With September 2026 commentary from the Shanghai government’s weekly foreign-invested information service now tracking the package in detail, the measures are the clearest single statement of where foreign pharma market access in China is heading this cycle.

Segmented production: from pilot to statute to rules

Segmented production (分段生产) distributes a drug’s manufacturing process across sites or companies — globally common, but long restricted in China. The progression:

  • October 2024: the National Medical Products Administration issued the pilot work plan for segmented production of biologics, allowing certain innovative and clinically urgent biologics to run segmented production at the pilot stage.
  • January 2026: the State Council published the revised Drug Administration Law Implementation Regulations, moving segmented production into institution. Article 31 provides that where a marketing-authorisation holder genuinely needs it, the holder may commission qualified manufacturers to segment-manufacture (i) innovative drugs with special process, facility or equipment requirements, (ii) clinically urgent drugs and drugs needed for public-health response or reserves identified by the State Council departments, and (iii) other drugs specified by the drug regulator. The holder must build a unified quality-assurance system covering the whole production process and all sites; vaccines and blood products carry their own commissioning rules.
  • Next step: the action plan’s commitment to issue implementation rules for segmented pharmaceutical production — the operational layer for application conditions, quality-responsibility allocation and regulatory coordination.

The commercial template already exists: in May 2026, Johnson & Johnson’s niccalimab injection became the first imported biologic to run domestic segmented production of drug substance — substance produced by WuXi Biologics in Wuxi, fill-finish completed by Vetter Pharma in Germany. For multinationals, the case demonstrates the operating model the rules will generalise: foreign marketing-authorisation holders placing upstream segments with qualified Chinese CDMOs while keeping downstream finishing abroad, or the reverse.

Biotechnology and wholly foreign-owned hospitals: pilot expansion pending approval

Biotechnology (human stem cells, gene diagnosis and therapy) has been open to FIEs only inside designated pilot areas since September 2024, when Beijing, Shanghai and Guangdong free trade zones and Hainan were authorised. The registry shows results: at least six foreign companies — including Merck, entities associated with JW Therapeutics (药明巨诺), Frontera Therapeutics (芳拓生物) and StarCellBio (星奕昂) — have completed business-scope changes or new registrations inside the pilot areas.

The action plan instructs authorities to expedite research and approval for expanding the pilot regions for both biotechnology and wholly foreign-owned hospitals — the same two openings that Shanghai’s 15th Five-Year plan and other provincial documents name as landing priorities. Neither expansion has been formally approved yet; the plan converts the expansion from discussion item into an official workstream with a deadline pressure attached.

Payment and channels: the last-mile package

Two measures address the revenue side that has historically capped foreign pharma’s China performance:

  • Commercial insurance. The plan supports insurers in bringing more innovative drugs and devices into commercial health-insurance coverage — the payer channel that has grown fastest as national reimbursement negotiations compress prices.
  • Retail channels. An industry collaboration platform will be built to facilitate foreign-produced pharmaceuticals entering drug retail channels — addressing the distribution friction that has kept foreign-manufactured drugs out of pharmacy chains even after approval.

What this means for foreign pharma and healthcare groups

  • Map your product portfolio against segmented-production eligibility. The statutory categories are innovative drugs with special process/equipment requirements and clinically urgent or reserve drugs; groups with biologics or special-technology chemicals should identify candidates and pre-qualify Chinese CDMO partners under a unified quality system.
  • Watch the implementation rules, not just the plan. Application conditions, quality-responsibility division and regulatory coordination sit in the forthcoming rules; the drafting is the moment to submit practical comments.
  • Treat pilot expansion as a siting decision. If the biotech and wholly-owned-hospital pilots extend to new provinces, entity location inside a pilot area becomes a structuring variable; hold new China healthcare investments until the expanded map is published.
  • Build the commercial-insurance and retail strategy now. Payment support and retail-channel facilitation are revenue-side measures; groups that prepare health-insurance dossiers and pharmacy distribution agreements can move when the platforms land.
  • Benchmark against the niccalimab case. The first segmented-production precedent defines the documentation and quality-system expectations regulators will apply to the next applications.

Sources

  • 济源产城融合示范区管理委员会(转载)— 商务部 国家发展改革委 财政部关于印发《利用外资固稳促优行动方案》的通知(商资发〔2026〕97号,2026年6月16日,政府官网全文): https://zt.www.jiyuan.gov.cn/zsyz/wstz_zsyz/zcfb/t1008712.html
  • 上海市人民政府外事办公室 — 《上海资讯周报》涉外资讯一站式服务(2026年9月第1期,总第157期,2026年9月2日,医药开放组合与分段生产制度演进综述): https://wsb.sh.gov.cn/ztzl/shzxzb/20260902/d2eb54ce238e4d6d9f5bcac6e428f6e6.html
  • 蒙城县人民政府(转载)— 中华人民共和国药品管理法实施条例(2026年修订版分段生产条款第31—33条全文): https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

Related reading

  • see also: segmented pharma production pilot mechanics (segmented-pharma-production)
  • see also: wholly foreign-owned hospital pilot requirements (foreign-owned-hospital-pilot)

外资行动方案中的医药开放组合:分段生产、试点扩围与支付渠道

概述

《利用外资固稳促优行动方案》(商资发〔2026〕97号)由商务部、国家发展改革委、财政部经国务院同意于2026年6月16日印发,其十五条举措中专设一条指向医药。该条为外资医药与生物技术企业组装了一套”生产—上市许可—支付—渠道”组合:分段生产实施细则、生物技术与外商独资医院试点扩围、商业保险支付支持与零售渠道便利。

随着2026年9月上海市政府涉外资讯周报对该政策包作出详细追踪解读,这是本周期内中国外资药品准入走向最清晰的一份单项表述。

分段生产:从试点到法定再到细则

分段生产(分段生产)把药品生产过程分布在不同场地或企业之间——全球通行,但在中国长期受限。演进脉络:

  • 2024年10月: 国家药监局印发生物制品分段生产试点工作方案,允许部分创新生物制品和临床急需生物制品在试点阶段开展分段生产。
  • 2026年1月: 国务院公布修订后的《药品管理法实施条例》,把分段生产推向制度。第三十一条规定,药品上市许可持有人确有需要的,可以委托符合条件的药品生产企业分段生产:(一)生产工艺、设施设备有特殊要求的创新药;(二)临床急需药品、应对突发公共卫生事件急需或储备需要的药品;(三)国务院药品监督管理部门规定的其他药品。持有人须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系;疫苗、血液制品另有委托生产规则。
  • 下一步: 行动方案承诺出台药品分段生产实施细则——即申请条件、质量责任划分与监管协调的操作层。

商业模板已经出现:2026年5月,强生制药的尼卡利单抗注射液成为全国首个开展原液境内分段生产的进口生物制品——原液由无锡药明生物生产,制剂由德国Vetter Pharma完成。对跨国药企而言,该案例演示了细则将要推广的运营模式:境外持有人把上游环节放在中国合格CDMO、下游制剂留在境外,或反向操作。

生物技术与外商独资医院:扩围报批中

自2024年9月北京、上海、广东自贸区和海南获准试点以来,生物技术(人体干细胞、基因诊断与治疗)仅对试点区域内FIE开放。登记情况已有产出:至少6家外资企业——包括默克、药明巨诺相关主体、芳拓生物(Frontera Therapeutics)、星奕昂等——已在试点区域内完成经营范围变更或新设登记。

行动方案要求抓紧研究报批进一步扩大生物技术、外商独资医院领域开放试点区域范围——上海”十五五”规划等省级文件点名的同样是这两项开放。扩围尚未正式获批;方案把扩围从讨论事项转为带时限压力的正式工作流程。

支付与渠道:最后一公里

两项措施指向历史上封顶外资药企中国收入的收入端:

  • 商业保险。 方案支持保险公司将更多创新药械纳入商业健康保险保障范围——在国家谈判压缩价格背景下增长最快的支付通道。
  • 零售渠道。 将搭建行业协作平台,便利外资企业生产的药品进入药品零售渠道——解决获批外资药品难以进入连锁药店的流通摩擦。

对外资医药与医疗集团的启示

  • 对照分段生产法定情形梳理产品组合。 法定类别是工艺设施有特殊要求的创新药与临床急需、储备药品;拥有生物制品或特殊工艺化学药的企业应识别候选产品,并按统一质量体系预审中国CDMO伙伴。
  • 盯细则而不止于方案。 申请条件、质量责任划分与监管协调都在即将出台的实施细则中;起草阶段是提交实务意见的窗口。
  • 把试点扩围当作选址变量。 若生物技术与独资医院试点扩展至新省份,主体落位在试点区域内就成为架构变量;新医疗投资可等扩围地图公布后再定。
  • 现在就建商保与零售策略。 支付支持与渠道便利是收入端措施;提前准备健康险材料与药店分销协议的集团,可在平台落地时立即行动。
  • 对标尼卡利单抗案例。 首个分段生产先例界定了监管对后续申请的单证与质量体系预期。

来源

  • 济源产城融合示范区管理委员会(转载)— 《利用外资固稳促优行动方案》通知全文(商资发〔2026〕97号): https://zt.www.jiyuan.gov.cn/zsyz/wstz_zsyz/zcfb/t1008712.html
  • 上海市人民政府外事办公室 — 《上海资讯周报》涉外资讯一站式服务(2026年9月第1期): https://wsb.sh.gov.cn/ztzl/shzxzb/20260902/d2eb54ce238e4d6d9f5bcac6e428f6e6.html
  • 蒙城县人民政府(转载)— 中华人民共和国药品管理法实施条例(分段生产条款全文): https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

相关阅读

  • 见:药品分段生产试点机制要点(segmented-pharma-production)
  • 见:外商独资医院试点要求(foreign-owned-hospital-pilot)

China professionalises the hospital channel for medical-nutrition foods: the FSMP Guiding Opinions

  • In late August 2026, the National Health Commission (NHC) and SAMR jointly issued the Guiding Opinions on Regulating the Use of Foods for Special Medical Purposes (FSMP) in Medical Institutions (document 国卫办食品发〔2026〕11号, dated 6 August 2026).
    2026年8月下旬,国家卫生健康委办公厅与市场监管总局办公厅联合印发《关于规范医疗机构特殊医学用途配方食品使用的指导意见》(国卫办食品发〔2026〕11号,成文日期2026年8月6日),面向各级各类医疗机构。
  • The Opinions define FSMP as formula foods registered by SAMR for sale on the domestic market, formulated for people with restricted eating, digestive-absorption disorders, metabolic disorders or specific disease states, and require use under the guidance of a physician or clinical nutritionist.
    指导意见界定:特医食品是指经国家市场监管部门注册可以在国内市场销售、为满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要专门加工配制的配方食品,须在医师或临床营养技师指导下使用。
  • Medical institutions must set up a dedicated FSMP management department or group, maintain a dynamic internal supply catalogue admitting only SAMR-registered products, and centralise selection, procurement, use and charging.
    医疗机构须确立特医食品使用管理部门或小组,建立并动态调整本机构《特殊医学用途配方食品供应目录》,只允许经国家注册的特医食品进入目录,并对遴选、采购、使用、收费进行集中统一管理。
  • Within hospitals, FSMP must be sold in a clearly marked dedicated zone or counter (“特殊医学用途配方食品销售专区/专柜”), sale and usage information must be recorded and retained to medical-record standards, and FSMP must not be prescribed as medicine — it is not a drug, so no prescriptions, and billing must be separated from pharmaceuticals.
    院内管理上,特医食品须设专区专柜销售并显著提示;销售信息(含患者信息、品名、规格、价格)记录保存时限参照病历;特医食品不属于药品、不得开具处方,发放与收费须与药品区分。
  • For imported and domestic FSMP producers and their distributors, the guidance professionalises the hospital channel: registration status will be verified at the hospital gate, procurement and recall co-operation with institutions is formalised, and marketing into hospitals must shift from prescription-style promotion to compliance-based clinical-nutrition education.
    对国内外特医食品企业与经销商而言,新规使医院渠道走向专业化:注册资质在医院门口被核验,采购与召回配合被制度化,面向医院的推广须从”类处方”促销转向合规的临床营养教育。

China professionalises the hospital channel for medical-nutrition foods: the FSMP Guiding Opinions | 特医食品医院渠道走向规范化:两部门出台医疗机构使用指导意见

Overview

The National Health Commission (NHC) and the State Administration for Market Regulation (SAMR) jointly issued the Guiding Opinions on Regulating the Use of Foods for Special Medical Purposes (FSMP) in Medical Institutions (《关于规范医疗机构特殊医学用途配方食品使用的指导意见》) in late August 2026, with the document dated 6 August 2026 and publicised around 26–30 August. The Opinions, issued under the Food Safety Law and the Regulations on the Administration of Medical Institutions, apply to the selection, sale and use of FSMP within all types and levels of medical institutions in China. They mark the first time the national authorities have set out a complete operational framework for how hospitals should manage, stock, sell and use FSMP — a category that sits at the intersection of food, nutrition and clinical care.

What FSMP are — and why they need special rules

FSMP are formula foods that have been registered by SAMR for sale on the domestic market, specially processed and formulated to meet the nutritional or dietary needs of people with restricted eating, digestive or absorption disorders, metabolic disorders, or specific disease states. They provide important nutritional support for treatment, rehabilitation and maintenance of bodily function in these populations. Because they look like medical products but are legally food, they have historically sat in an ambiguous zone: food law governs their registration, yet their practical use is clinical, and hospitals have lacked uniform rules on procurement, pricing, storage and use.

The Opinions restate the fundamental boundary: FSMP must be used under the guidance of a physician or clinical nutritionist, and they are not drugs. The document applies to medical institutions holding a Medical Institution Practicing Licence or clinic-filing certificate.

Three layers of institutional rules

1. Governance structure. Each medical institution must establish a dedicated FSMP management department or group, build and dynamically adjust its own internal FSMP supply catalogue, verify product qualifications, and admit only FSMP registered by SAMR. The institution must set up rules for selection, review, procurement, use, periodic evaluation and exit, managing FSMP centrally and standardising the processes for receiving, using and charging.

2. In-hospital management systems. Institutions must take effective control measures across procurement, storage, sale and use; establish and refine systems for incoming-goods inspection and record-keeping (进货查验记录制度), warehouse management, in-and-out management, and handling of non-conforming FSMP; and designate personnel responsible for food-safety management. Practitioners involved in FSMP use — physicians or clinical nutritionists — should have clinical-nutrition education or training, plus FSMP-use knowledge and standardised-management training.

3. Clinical-use discipline. Practitioners should follow a standardised nutrition-diagnosis-and-treatment pathway, giving priority to dietary guidance and only proposing FSMP where dietary intervention cannot meet clinical needs and there are clinical indications. When recommending FSMP, they should explain the product’s details and its non-drug nature, whether alternative food or medicine exists, and obtain patient or family consent where used. FSMP use during a hospital stay should be recorded in the medical record, and the institution’s FSMP management department or group should evaluate the standardisation and reasonableness of use.

Selling and charging rules that matter commercially

Four operational rules are particularly important for producers and distributors:

  • Dedicated zone or counter. Institutions that sell FSMP must set up a separate sales area with a prominent sign reading “特殊医学用途配方食品销售专区(或专柜)”.
  • Record retention. Sales information — including patient information, FSMP name, specification and price — must be recorded and kept for a retention period consistent with medical records. This is a significant compliance consideration under the Personal Information Protection Law for patient-related data.
  • No prescriptions; separate billing. FSMP are not drugs, so they cannot be prescribed; their distribution and charging must be separated from pharmaceuticals. Institutions are encouraged to adopt information-system coding management that brings FSMP sales and use into hospital information systems.
  • No coercion. It is prohibited to sell or use, in the name of FSMP, any food that is not registered or that implies it can meet the special nutritional or dietary needs of the target populations. It is also prohibited to force or induce patients to buy FSMP in the institution or at designated outlets.

Recall co-operation

Institutions must co-operate with FSMP producers on recalls: once aware that a producer is recalling unsafe FSMP, the institution must immediately stop selling and seal the product and post a recall notice in a prominent position. Producers should therefore ensure their recall procedures reach hospital customers promptly and are documented.

What this means for producers and distributors

  • Registration is the admission ticket to the hospital channel. Hospitals may only list SAMR-registered FSMP in their supply catalogues. For importers, this reinforces the existing requirement to hold a Chinese registration for each product sold in China; products without registration cannot legally enter the hospital channel regardless of clinical demand.
  • The path to hospital formulary entry is now formal. Producers should expect hospital procurement to be run through the dedicated management group, with qualification review, and periodic re-evaluation. Building clinical-nutrition evidence and co-operation with nutrition departments — rather than prescription-oriented promotion — becomes the compliant route to market access.
  • Compliance burden moves down the chain. Distributors serving hospitals must ensure that labelling, storage and delivery meet the dedicated-zone and traceability expectations, and that patient-related sales data handling complies with privacy rules.
  • Regional variation is expected. The Opinions acknowledge that regions differ in economic development, medical-resource allocation and clinical-nutrition development, and encourage local implementation adapted to local conditions. Producers should track provincial implementation measures.
  • Opportunity in the nutritional-support gap. With an ageing population and growing awareness of clinical nutrition, FSMP remain a growth category; clearer rules that professionalise the hospital channel can favour compliant, well-evidenced brands — domestic and foreign alike.

Practical steps

  • Verify that every FSMP product marketed into China holds a valid SAMR registration matching the exact formula and label in use.
  • Prepare hospital-facing materials that support nutrition-department education and formulary review (clinical evidence summaries, usage guidance compliant with non-drug positioning).
  • Ensure recall plans include hospital customers and rapid notification mechanisms.
  • Review distributor agreements for compliance with dedicated-zone sale, record-retention and no-coercion rules.
  • Monitor provincial implementation guidance and adjust sales models per region.

Sources

  • 市场监管总局 — 国家卫生健康委办公厅 市场监管总局办公厅关于规范医疗机构特殊医学用途配方食品使用的指导意见(全文): https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/tssps/art/2026/art_81290de7385d4573939b6790103a5fb1.html
  • 市场监管总局(新闻)— 两部门联合出台指导意见 规范医疗机构使用特殊医学用途配方食品: https://www.samr.gov.cn:8007/xw/zj/art/2026/art_b34e6b283ecf4530a93aef63c6194e9f.html
  • 毕节市人民政府(政策解读转载)— 划红线、建目录、禁开处方!国家出台新规规范特医食品使用: https://www.bijie.gov.cn/bm/bjswsjkj/zwgk/zcwjjjd/202608/t20260831_90801118.html
  • 人民网湖北频道 — 国家卫生健康委等规范医疗机构特医食品使用管理: https://hb.people.com.cn/n2/2026/0831/c192237-41681914.html

Related reading

  • see also: China’s FSMP registration regime — the 2024 Administrative Measures baseline (fsmp-registration-measures)
  • see also: medical-device and pharma market entry routes into Chinese hospitals (healthcare-market-access)

特医食品医院渠道走向规范化:两部门出台医疗机构使用指导意见

概述

2026年8月下旬,国家卫生健康委办公厅与市场监管总局办公厅联合印发《关于规范医疗机构特殊医学用途配方食品使用的指导意见》(成文日期2026年8月6日,8月26日前后对外发布)。指导意见依据《食品安全法》《医疗机构管理条例》等法律法规制定,适用于各级各类医疗机构内特医食品的遴选、销售与使用,是国家层面首次为医院如何管理、采购、销售和使用特医食品建立完整操作框架。特医食品正处于食品、营养与临床照护的交叉地带,此前的管理长期存在模糊区。

什么是特医食品——以及为何需要专门规则

特医食品是指经国家市场监管部门注册可以在国内市场销售,为满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要,专门加工配制而成的配方食品。对这些人群的治疗、康复及机体功能维持起着重要营养支持作用。它看起来像医疗产品、法律上却是食品:注册环节适用食品法,实际使用却是临床行为,医院在采购、定价、储存与使用上长期缺乏统一规则。

指导意见重申根本边界:特医食品须在医师或临床营养技师指导下使用,且不属于药品。文件适用于持有《医疗机构执业许可证》或诊所备案凭证、依法从事疾病诊断和治疗活动的诊疗机构。

三层制度要求

一、治理架构。 医疗机构须确立特医食品使用管理部门或小组,建立并动态调整本机构《特殊医学用途配方食品供应目录》,审核产品资质,只允许经国家市场监管部门注册的特医食品进入目录。医院要建立遴选、审核、采购、使用、定期评估和退出制度,对特医食品集中统一管理,规范领取、使用与收费流程。

二、院内管理制度。 医院须在采购、贮存、销售及使用等环节采取有效控制措施,建立健全进货查验记录制度、仓储场所管理制度、出入库管理制度及不合格特医食品处置制度,明确负责食品安全管理的人员。从事特医食品使用工作的医师或临床营养技师等,应经过临床营养专业教育或培训,以及特医食品使用知识和规范化管理培训。

三、临床使用规范。 医师或临床营养技师应严格遵照规范化营养诊疗流程,优先提出膳食指导建议;膳食干预无法满足临床需求时,方可根据临床应用指征提出必要的特医食品使用建议。提出建议时应说明食品详情和非药品属性、是否有可替代的食品或药品,使用应征得患者或家属同意。患者住院期间使用特医食品的情况应记入病历,医院特医食品使用管理部门或小组应组织评估使用规范性与合理性。

对商业运营至关重要的销售与收费规则

以下四项操作性规则对生产企业和经销商尤其关键:

  • 专区专柜。 医疗机构经营特医食品,应设专门的销售区域,显著位置设提示牌,注明”特殊医学用途配方食品销售专区(或专柜)”字样。
  • 信息留存。 对销售信息(含患者信息、特医食品名称、规格、价格)进行记录和保存,保存时限参照病历。涉及患者信息的数据处理须同时符合《个人信息保护法》等要求。
  • 不得开处方、收费分离。 特医食品不属于药品、不得开具处方,其发放、收费等应当与药品区分;鼓励有条件的机构做好信息业务编码管理,将特医食品销售和使用项目纳入院内信息系统。
  • 禁止强制销售。 严禁以特医食品名义销售或使用未经国家注册批准、明示或暗示可用于满足目标人群特殊营养或膳食需要的食品;严禁强制或诱导患者在本机构或到指定地点购买。

召回配合

医疗机构应配合特医食品生产企业开展召回:一旦知悉企业召回不安全特医食品,应立即停止销售并封存、在醒目位置张贴召回公告。生产企业应确保召回程序能及时触达医院客户并留存记录。

对企业与经销商的意义

  • 注册资质是进入医院渠道的门票。 医院目录只接纳经国家注册的特医食品。进口商须为在华销售的每个产品持有有效中国注册证;无注册证的产品无论临床需求多大都无法合法进入医院渠道。
  • 进入院内目录的路径正式化。 生产企业应预期采购由专门管理小组按资质审核与定期再评估流程运作。建立临床营养证据、与营养科开展合规合作,而非”类处方”式促销,成为合规的市场准入路径。
  • 合规压力沿渠道下移。 服务医院的经销商须确保标签、储存与配送满足专区与可追溯预期,涉患者销售数据的处理符合隐私规则。
  • 地区差异可期。 指导意见承认各地在经济发展水平、医疗资源配置与临床营养学科建设上存在差异,鼓励各地结合本地实际实施。企业应跟踪省级落实细则。
  • 营养支持缺口中的机遇。 在人口老龄化与临床营养意识提升背景下,特医食品仍是增长品类;医院渠道专业化的清晰规则,将有利于合规、有证据的国内外品牌。

实务建议

  • 核验在华销售的每个特医食品产品均持有与在用配方、标签一致的有效的国家注册证。
  • 准备面向医院的合规材料,支持营养科教育与目录评审(临床证据摘要、符合非药品定位的使用指引)。
  • 确保召回计划覆盖医院客户并具备快速通知机制。
  • 审查经销商协议,确保其遵守专区销售、记录留存与禁止强制销售规则。
  • 跟踪各省级实施指引,分区域调整销售模式。

来源

  • 市场监管总局 — 国家卫生健康委办公厅 市场监管总局办公厅关于规范医疗机构特殊医学用途配方食品使用的指导意见(全文): https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/tssps/art/2026/art_81290de7385d4573939b6790103a5fb1.html
  • 市场监管总局(新闻)— 两部门联合出台指导意见 规范医疗机构使用特殊医学用途配方食品: https://www.samr.gov.cn:8007/xw/zj/art/2026/art_b34e6b283ecf4530a93aef63c6194e9f.html
  • 毕节市人民政府(政策解读转载)— 划红线、建目录、禁开处方!国家出台新规规范特医食品使用: https://www.bijie.gov.cn/bm/bjswsjkj/zwgk/zcwjjjd/202608/t20260831_90801118.html
  • 人民网湖北频道 — 国家卫生健康委等规范医疗机构特医食品使用管理: https://hb.people.com.cn/n2/2026/0831/c192237-41681914.html

相关阅读

  • 见:中国特医食品注册管理——《注册管理办法》(2024年施行)基线(fsmp-registration-measures)
  • 见:药品与医疗器械进入中国医院市场的路径(healthcare-market-access)

China’s drug traceability rules harden: full coding, full scanning from NMPA Announcement No. 85 of 2026

  • On 1 September 2026, the National Medical Products Administration (NMPA) published Announcement No. 85 of 2026 on Further Strengthening the Administration of Drug Information Traceability (dated 31 August 2026), demanding full-variety coding (“应赋尽赋”) and full-chain scanning (“见码必扫”).
    2026年9月1日,国家药监局发布《关于进一步加强药品信息化追溯管理工作的公告》(2026年第85号,落款2026年8月31日),提出”全品种赋码、应赋尽赋,全链条扫码、见码必扫”的总要求。
  • The announcement hardens legal duties across the whole chain — marketing-authorisation holders (MAHs), domestic agents of overseas MAHs, manufacturers, distributors, medical institutions and traceability-system operators — and, with limited exceptions (active pharmaceutical ingredients, medical oxygen, hospital preparations), all finished dosage forms in production must be coded; TCM decoction pieces follow separate rules.
    公告压实持有人、境外持有人指定境内责任人、生产企业、经营企业、使用单位及追溯系统运营单位等各方责任;除原料药、医用氧、医疗机构制剂等少数品类外,全部在产制剂品种均须赋码(中药饮片追溯要求另行制定)。
  • Code registration is tightened: MAHs and domestic agents must file drug identifier codes on the national co-ordination platform through the NMPA government-service portal and link identifier code, commodity bar code, national drug code and medical-insurance code; issuing bodies and system operators must also file to guarantee uniqueness.
    追溯码备案趋严:持有人、境内责任人须通过国家药监局政务服务门户登录国家药品追溯协同服务平台,及时准确完整备案药品标识码,完成标识码、商品条码、本位码、医保编码等多码关联;发码机构与系统运营单位须向平台备案以确保唯一性。
  • Distributors and end-users face hard scanning rules: wholesalers must treat code verification as a mandatory part of inbound acceptance and upload information on outbound review; pharmacies and medical institutions must verify codes on inbound acceptance, upload sales records, and refuse goods whose traceability shows they were already sold at another retail outlet; abnormal alerts require stopping sales pending quality-manager review.
    经营使用环节扫码成为硬性流程:批发企业须把扫码核对作为入库验收的必须内容并在出库复核时上传信息;零售药店与医疗机构入库验收须核对追溯码、销售时上传销售信息;发现追溯信息显示药品已在其他零售或使用单位售出的应拒收;出现异常预警应立即停止入库和销售,由质量负责人审核签字后处理。
  • For pharmaceutical companies importing into China and their local partners, the message is that traceability has moved from infrastructure-building to routine enforcement: performance will be woven into daily inspections by provincial drug administrations, with tampering or fabrication of traceability data punished under the Drug Administration Law and GSP-related rules.
    对进口药品企业与本地合作伙伴而言,信号明确:药品追溯已从”建基础设施”进入”常态化监管执法”阶段——省级药监部门将把追溯落实情况纳入日常检查,篡改、伪造追溯数据或不落实追溯义务者将依《药品管理法》《药品经营和使用质量监督管理办法》等严肃处理。

China’s drug traceability rules harden: full coding, full scanning from NMPA Announcement No. 85 of 2026 | 药品追溯进入”全品种全链条”强监管:国家药监局2026年第85号公告解读

Overview

On 1 September 2026, the National Medical Products Administration (NMPA) published Announcement No. 85 of 2026 on Further Strengthening the Administration of Drug Information Traceability (《国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号)》), dated 31 August 2026. Building on the Drug Administration Law and its implementing regulations, the announcement consolidates years of pilot infrastructure into a compulsory, enforceable regime: every product coded, every code scanned, and every link answerable. NMPA officials described the drug traceability code as each pack’s “electronic identity card”, capable of recording where a product has been approved and how it moved through production and distribution.

The core principle: 应赋尽赋, 见码必扫

The announcement states the overall requirement as “full-variety coding — everything that should be coded must be coded; full-chain scanning — every code that appears must be scanned”. The coverage is nearly universal: with the exceptions of active pharmaceutical ingredients, medical oxygen and hospital preparations, all finished dosage forms in production fall within the traceability scope. Traditional Chinese medicine decoction pieces are governed by separate rules to be issued. This means imported finished drugs distributed in China are squarely within the regime, and their MAHs and domestic agents carry the first-layer obligations.

Duties by link in the chain

MAHs and domestic agents of overseas MAHs (持有人、境内责任人). They must:

  • file drug identifier codes through the NMPA government-service portal on the national drug traceability co-ordination platform, accurately and completely, linking the identifier code, commodity bar code, national drug code (本位码) and medical-insurance code;
  • follow the “one object one code, code and object tracked together” (一物一码、物码同追) principle, completing traceability-code activation before market launch, linking codes across all levels of sales packaging, and uploading traceability information accurately and promptly;
  • save in-warehouse records in the traceability system at finished-goods receipt, provide downstream traceability information at outbound sale, and promptly handle abnormal-code feedback from downstream parties so that information remains truthful and credible.

Manufacturers (生产企业). Alongside MAHs, they are responsible for coding activation and packaging-linkage before products are placed on sale, and for accurate, timely uploads.

Wholesale distributors (批发企业). Inbound acceptance must include obtaining traceability information from the upstream party and verifying the traceability code as a mandatory part of acceptance; they must feed receipt information back upstream and, at outbound-sale review, provide traceability information to downstream enterprises or medical institutions through the system.

Retail pharmacies and medical institutions (零售药店、医疗机构). On inbound acceptance they must verify codes against the upstream party and feed receipt information back; when selling, they must keep detailed sales records and upload sales information through the traceability system in a timely manner. Sales receipts must display the traceability code or offer another convenient query channel for consumers. Where the system raises an abnormal alert, the pharmacy or institution must immediately stop inbound acceptance and sales, verify and handle the alert, with the measures signed off by the quality manager and records kept per GSP requirements. Where inbound acceptance reveals traceability information showing the drug was already sold at a retail pharmacy or medical institution, the goods must be refused.

Traceability-system operators (追溯系统运营单位). They must maintain public-interest orientation, guarantee data security, provide recall support for MAHs and domestic agents, offer real-time early warning of abnormal traceability signals at inbound acceptance for wholesale, retail and user units, protect personal privacy and trade secrets in traceability data, and not disclose or illegally provide data to others. They must file with the national platform to ensure code uniqueness.

Supervision and enforcement

The announcement asks provincial drug administrations to make traceability performance part of daily inspection of enterprises and units in their regions, pushing full-variety coding activation and full-chain scanning and uploading (“应赋尽赋、应扫尽扫”). Entities that fail to comply with the regulations or with traceability requirements are to be handled seriously under the Drug Administration Law, the Measures for the Supervision and Administration of Drug Operation and Use, and the Good Supply Practice (GSP) rules. NMPA also stresses “三医协同” — co-ordination among the drug, medical-insurance and health authorities — and the use of traceability data for smart supervision, risk discovery and rapid handling. The data-security angle is explicit: system operators must build data-security management institutions under the Data Security Law and keep private and commercial data confidential.

Why this matters to foreign pharmaceutical companies

  • Traceability compliance is now an enforcement matter, not a project. Foreign MAHs importing finished drugs must ensure their domestic agent (境内责任人) operates the full coding-and-uploading cycle on the national platform. The agent is a regulated extension of the MAH; a weak agent means personal exposure for the MAH’s China compliance posture.
  • Multi-code linkage affects packaging and IT work. Linking the identifier code, commodity bar code, national drug code and medical-insurance code means packaging data and enterprise resource systems must be reconciled with Chinese regulatory identifiers before first import. Imported products already carrying GS1 codes still need the Chinese identifier-code linkage.
  • Channel discipline improves for compliant players. The rule that goods already sold elsewhere must be refused, and that abnormal alerts stop sales, directly attacks “reflux drugs” (回流药) and code-swapping fraud — problems that undercut legitimate pricing. Compliant importers benefit as grey channels close.
  • GSP-grade documentation is required across the distributor network. Distributors’ inbound/outbound scanning and the quality-manager sign-off on abnormal alerts become audit evidence; foreign firms should verify their Chinese distributors’ systems actually generate this documentation.
  • Co-ordination with medical-insurance settlement. NMPA links traceability to medical-insurance code-based settlement; announcements and practice increasingly tie code verification to reimbursement and anti-fraud work, so products without sound traceability data may face friction in hospital and insurance-channel reimbursement.

Practical steps

  • Confirm that the domestic agent of each imported MAH has an up-to-date registration on the national traceability co-ordination platform with correct multi-code linkage for every marketed SKU.
  • Audit packaging and labelling projects to ensure traceability codes, bar codes and hierarchy linkage are complete before first shipment into China.
  • Review distributor contracts to require GSP-compliant inbound/outbound scanning, abnormal-alert handling and quality-manager sign-off records.
  • Align internal ERP/quality systems with the platform’s data-upload requirements, including timely handling of downstream abnormal-code feedback.
  • Monitor provincial enforcement and any TCM-decoction-piece traceability rules still to be issued, and track the interaction between traceability and medical-insurance settlement in tender and hospital channels.

Sources

  • 国家药监局 — 国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260901134430105.html
  • 医药网 — 药品追溯新规出台 压实全产业链主体监管责任: https://news.pharmnet.com.cn/news/2026/09/02/625299.html
  • 央视新闻(辽宁药监转载)— 视频丨国家药监局:药品追溯须覆盖全品种全链条: https://www.toutiao.com/article/7681111672232100387

Related reading

  • see also: China’s drug import licensing and GSP obligations for foreign MAHs (drug-import-licensing-gsp)
  • see also: medical-device UDI roll-out and the parallel “drug-device same-traceability” agenda (medical-device-udi)

药品追溯进入”全品种全链条”强监管:国家药监局2026年第85号公告解读

概述

2026年9月1日,国家药监局发布《关于进一步加强药品信息化追溯管理工作的公告》(2026年第85号,落款2026年8月31日)。公告依据《药品管理法》及其实施条例制定,把多年试点形成的基础设施升级为强制性、可执行的全链条制度:每个产品赋码、每个码必扫、每个环节可追责。药监局官员将药品追溯码形容为每一盒药的”电子身份证”,扫码即可记录和获取药品获批及生产流通环节的详细信息。

总原则:应赋尽赋、见码必扫

公告确立的总要求是”全品种赋码、应赋尽赋;全链条扫码、见码必扫”。覆盖面近乎全面:除原料药、医用氧、医疗机构制剂等少数品类外,全部在产制剂品种纳入追溯范围;中药饮片追溯要求另行制定。这意味着在华流通的进口制剂同样完全落入该制度,其持有人与境内责任人承担第一层义务。

各环节义务

持有人、境外持有人境内责任人。 须:通过国家药监局政务服务门户登录国家药品追溯协同服务平台,及时、准确、完整备案药品标识码,完成标识码、商品条码、本位码、医保编码等多码关联;按照”一物一码、物码同追”原则,在上市销售前完成追溯码赋码激活、各级销售包装单元追溯码关联并及时准确上传追溯信息;成品入库时在追溯系统保存入库信息,销售出库时向下游企业或使用单位提供追溯信息;及时处理下游反馈的追溯码异常信息,保障信息真实可信。

生产企业。 与持有人共同落实赋码激活与包装层级关联,及时准确上传信息。

批发企业。 入库验收时必须通过追溯系统向上游索取追溯信息、进行追溯码核对,将扫码核对作为入库验收的必须内容并反馈收货信息;出库复核时向下游企业或医疗机构提供追溯信息。

零售药店与医疗机构。 入库验收时与上游核对追溯码并反馈收货信息;销售时保存销售记录明细并及时上传销售信息;销售小票应显示追溯码或提供便捷查询渠道。追溯系统出现异常预警的,应立即停止入库和销售,核实处理并由质量负责人审核签字后实施,按GSP要求保存记录。入库验收发现追溯信息显示该药品已在其他零售或使用单位售出的,应当拒收。

追溯系统运营单位。 坚持公益性导向,保障数据安全;为持有人、境内责任人提供召回支持;为批发、零售、使用单位提供入库环节异常信号实时预警;对追溯信息中可能含有的个人隐私、商业秘密依法保密,不得泄露或非法提供;向国家平台备案确保追溯码唯一性。

监管与执法

公告要求各省级药监部门把追溯落实情况纳入对企业和单位的日常检查,督促做好全品种赋码激活与全链条扫码上传,做到”应赋尽赋、应扫尽扫”。对不落实法规规定、不符合追溯工作要求的,依照《药品管理法》《药品经营和使用质量监督管理办法》《药品经营质量管理规范》等严肃处理。公告强调”三医协同”(药监、医保、卫健),依托大数据智慧监管,提升风险发现与处置能力。数据安全要求明确:系统运营单位须依《数据安全法》建立数据安全管理制度。

对外资药企的意义

  • 追溯合规进入执法阶段,不再是”项目”。 进口制剂的外国持有人必须确保其境内责任人在国家平台完整运行赋码与上传闭环。境内责任人是持有人监管职能的延伸;责任人履职不力将直接拖累持有人整体在华合规态势。
  • 多码关联影响包装与IT工作。 标识码、商品条码、本位码、医保编码的关联意味着包装数据与ERP系统须在首次进口前与中国监管标识体系对齐。已带GS1条码的进口产品仍需完成中文标识码关联。
  • 合规玩家的渠道秩序改善。 “已在别处售出即拒收”与”异常预警即停售”直击回流药与串换编码乱象——这些乱象侵蚀合法定价体系。灰色渠道收窄,合规进口商受益。
  • 分销网络需具备GSP级文档能力。 分销商出入库扫码与质量负责人对异常预警的签字成为审计证据;外企应核实中国分销商系统确实能生成此类记录。
  • 与医保结算联动。 追溯与依码结算政策协同,扫码核验日益与报销、基金稽查挂钩;追溯数据不健全的产品在医院与医保渠道的报销可能受阻。

实务建议

  • 确认每个进口上市许可持有人的境内责任人在国家追溯协同平台登记有效,且每个在售SKU多码关联正确。
  • 审计包装与标签项目,确保追溯码、条码与层级关联在首次进入中国市场前完备。
  • 修订经销商合同,要求GSP合规的出入库扫码、异常预警处理与质量负责人签字记录。
  • 将内部ERP/质量系统与国家平台数据上传要求对齐,包括及时处理下游异常码反馈。
  • 跟踪省级执法动态与待出台的中药饮片追溯规则,并关注集采挂网与医院渠道中追溯与医保结算的衔接。

来源

  • 国家药监局 — 国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260901134430105.html
  • 医药网 — 药品追溯新规出台 压实全产业链主体监管责任: https://news.pharmnet.com.cn/news/2026/09/02/625299.html
  • 央视新闻(辽宁药监转载)— 视频丨国家药监局:药品追溯须覆盖全品种全链条: https://www.toutiao.com/article/7681111672232100387

相关阅读

  • 见:外国持证人的药品进口许可与GSP义务(drug-import-licensing-gsp)
  • 见:医疗器械UDI分批强制与”药械同追”议程(medical-device-udi)

Declaring psychotropic drug imports and exports: NMPA-GACC Announcement 2026 No. 84

  • The National Medical Products Administration (NMPA) and the General Administration of Customs (GACC) jointly published Announcement 2026 No. 84 on 28 August 2026, providing the customs HS commodity numbers to reference when declaring import or export of newly controlled medicinal psychotropic substances.
    2026年8月28日,国家药监局与海关总署联合发布2026年第84号公告,就新列入管制范围的药用类精神药品的进出口申报,公布供通关申报参考的海关商品编号。
  • The announcement follows a separate joint decision by NMPA, the Ministry of Public Security and the National Health Commission adding three substances to the medicinal psychotropic substance catalogue: methoxyetomidate, leretomidate and sonanfetomide — with exceptions for drug preparations approved for marketing in China.
    公告之前,国家药监局、公安部、国家卫生健康委联合发布调整公告,将甲氧依托咪酯、乐瑞托咪酯、索安非托增列入药用类精神药品目录(在中国境内批准上市的相应药品制剂除外)。
  • The published commodity numbers cover only part of the controlled goods; importers and exporters whose actual goods fall outside the listed numbers must declare truthfully rather than assume exemption.
    公布的编号仅包含管制商品中的部分商品;实际进出口商品超出相关商品编号范围的,应当如实申报,而非推定不涉管制。
  • The rules anchor to the Drug Administration Law and the Customs Law: medicinal psychotropic substances remain subject to import/export permit and reporting disciplines administered by NMPA and customs.
    新规以《药品管理法》《海关法》为法律依据:药用类精神药品进出口仍适用由国家药监局与海关管理的准许证与申报纪律。
  • The announcement takes effect on 1 October 2026, giving pharmaceutical importers, exporters and CRO/logistics partners a one-month window to update screening and declaration procedures.
    公告自2026年10月1日起施行,为医药进出口企业、研发外包与物流伙伴留下约一个月时间更新筛查与申报流程。
  • For pharmaceutical companies shipping controlled APIs or finished drugs in or out of China, the practical task is to verify each SKU against the expanded catalogue and the new commodity numbers, and to keep records showing the actual substance and formulation status.
    对进出境受管制原料药或制剂的企业而言,实操要点是逐一核对产品品目是否落入扩围后的目录与新商品编号,并留存能证明实际物质与制剂状态的记录。

Declaring psychotropic drug imports and exports: NMPA-GACC Announcement 2026 No. 84 | 药用类精神药品进出口申报新规:国家药监局 海关总署2026年第84号公告解读

Overview

On 28 August 2026 the National Medical Products Administration (NMPA) and the General Administration of Customs (GACC) published Announcement 2026 No. 84 — Matters Concerning the Declaration of Import and Export of Medicinal Psychotropic Substances (国家药监局 海关总署关于药用类精神药品进出口申报事项的公告). The announcement sets out the customs HS commodity numbers to reference when declaring imports or exports of varieties that were recently added to the medicinal psychotropic substance catalogue, and takes effect on 1 October 2026.

The announcement sits on top of an earlier regulatory step: NMPA, the Ministry of Public Security and the National Health Commission jointly issued a decision adjusting the medicinal psychotropic substance catalogue, adding methoxyetomidate, leretomidate and sonanfetomide to the list — except for drug preparations containing these substances that have been approved for marketing in China. Announcement 2026 No. 84 was then issued under the Drug Administration Law and the Customs Law to give traders concrete reference numbers for customs declaration.

Why this matters

China exercises strict control over psychotropic substances under its drug-control system, and the import and export of such substances requires permits and compliant declaration. The significance of this announcement is twofold:

  1. The control scope just widened. Three substances — methoxyetomidate, leretomidate and sonanfetomide — have been added to the medicinal psychotropic substance catalogue. Any company shipping these substances into or out of China (outside the China-approved formulation carve-out) now falls within the controlled-substance regime.
  2. Customs now has published reference codes. By giving HS commodity numbers for the newly added varieties, NMPA and GACC intend to reduce ambiguity at the border so that declarations are consistent and shipments are not held up by classification disputes.

The key provisions

  • Reference commodity numbers. The announcement publishes the customs commodity numbers for the newly listed varieties, for reference in customs declaration.
  • Partial coverage. The announcement expressly states that the commodity numbers cover only *part* of the controlled goods. If the actual goods being imported or exported fall outside the listed commodity-number range, the declarant must still declare truthfully.
  • Legal basis. The announcement is issued under the Drug Administration Law, the Customs Law and related laws and regulations.
  • Effective date. 1 October 2026.

The honest-declaration clause is the operative discipline: the commodity numbers are a facilitation tool, not a safe harbour. A shipment containing a newly controlled substance but classified under a different HS number remains subject to the controlled-substance rules, and the declarant bears the duty to reflect the true nature of the goods.

Context: the wider psychotropic-substance framework

Medicinal psychotropic substances are regulated separately from narcotic drugs but within the same family of controlled-substance rules. Imports and exports generally require permits issued through the drug-administration system, and customs releases goods against those permits together with normal declaration documents. Companies trading in active pharmaceutical ingredients (APIs) or finished drugs that touch the controlled list must:

  • verify whether each product contains a catalogue substance;
  • confirm whether a China-approved formulation exception applies;
  • obtain the appropriate permits before shipment; and
  • declare accurately at customs using the published reference codes where applicable.

What companies should do before 1 October 2026

For pharmaceutical importers and exporters — including foreign companies shipping APIs into China for contract manufacturing, or exporting controlled finished products — the practical checklist is:

  • Re-screen the product portfolio. Compare every SKU in the import/export pipeline against the expanded medicinal psychotropic catalogue, paying attention to the three new substances by both Chinese and international names.
  • Map the formulation exception. The catalogue addition excludes drug preparations approved for marketing in China. Confirm whether the product you ship is such an approved preparation and keep supporting registration documents in the compliance file.
  • Update declaration masters. Where a controlled substance is involved, update product masters, customs-classification records and the reference commodity numbers so that declarations after 1 October use the correct codes.
  • Check permit status. Confirm that the necessary import/export permits are in place and that the responsible internal or third-party declarant understands the split of duties between NMPA permits and customs release.
  • Prepare for audits. Regulators and customs may test whether declared goods match actual substance content. Retain certificates of analysis, formulation sheets and supply-chain records that demonstrate the true state of each shipment.
  • Brief logistics and CRO partners. If a third party handles declaration or cross-border logistics, circulate the announcement so screening updates are applied across the chain, not only at the licence holder.

Practical notes for foreign pharmaceutical companies

Foreign companies most affected are those that supply or buy the three newly controlled substances — or that manufacture medicines where these substances appear as intermediates or impurities above applicable thresholds. Points worth noting:

  • The announcement is a border-declaration facilitation measure; it does not by itself change the permit regime, which continues to apply to controlled substances.
  • The “approved formulation” carve-out is narrow: it protects drug preparations approved for marketing in China, not raw substances or unapproved preparations.
  • Given the 1 October effective date, any shipment booked for late September and arriving in October should be screened under the new scope to avoid a compliance gap.

Sources

  • 国家药品监督管理局 — 国家药监局 海关总署关于药用类精神药品进出口申报事项的公告(2026年第84号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902092356142.html
  • 中华人民共和国海关总署 — 政务公告列表(含2026年第84号、第128号、第129号等): http://www.customs.gov.cn/
  • 医药魔方 — 药用类精神药品进出口申报事项公告(品种与施行日期摘要): https://bydrug.pharmcube.com/news/detail/484ba2600ed6d80d29192ad8ba49dca8

Related reading

  • see also: China’s 2026 customs clearance guide for the ninth CIIE (370-ciie-2026-customs-clearance-guide)
  • see also: Guangdong’s international medical services pilot and pharma investment (329-guangdong-international-medical-services)

药用类精神药品进出口申报新规:国家药监局 海关总署2026年第84号公告解读

概述

2026年8月28日,国家药品监督管理局与海关总署联合发布《关于药用类精神药品进出口申报事项的公告》(2026年第84号),就近期增列入药用类精神药品目录的品种,公布供进出口通关申报参考的海关商品编号。公告自2026年10月1日起施行。

公告建立在更早一步的监管动作之上:国家药监局、公安部、国家卫生健康委联合发布调整药用类精神药品目录的公告,将甲氧依托咪酯、乐瑞托咪酯、索安非托增列入药用类精神药品目录(在中国境内批准上市的含上述物质的药品制剂除外)。随后,依据《药品管理法》《海关法》等法律法规,2026年第84号公告出台,为贸易企业提供具体的通关申报参考编号。

为何重要

中国在药物管制体系下对精神药品实行严格管控,此类物质的进出口需取得准许证并合规申报。本次公告的意义有二:

  1. 管制范围刚刚扩大。 甲氧依托咪酯、乐瑞托咪酯、索安非托三个品种被增列入药用类精神药品目录。任何将上述物质运入或运出中国的企业(中国批准上市制剂除外),如今均落入管制物质制度范畴。
  2. 海关有了公开的参考编码。 通过为新增品种提供海关商品编号,国家药监局与海关总署意在减少口岸的归类不确定性,使申报口径一致,避免货物因归类争议而被滞留。

主要条款

  • 参考商品编号。 公告公布新增列品种的海关商品编号,供通关申报参考。
  • 部分覆盖。 公告明确,公布的编号仅包含管制商品中的部分商品。实际进出口商品超出相关商品编号范围的,仍应当如实申报。
  • 法律依据。 公告依据《药品管理法》《海关法》等法律法规制定。
  • 施行日期。 2026年10月1日。

“如实申报”条款是操作性纪律:商品编号是便利工具,而非安全港。一批含有新管制物质但归入其他HS编码的货物,仍适用管制物质规则,申报人有义务如实反映货物的真实属性。

背景:更宽的精神药品监管框架

药用类精神药品与麻醉药品分列管制,但同属管制物质规则体系。其进出口一般需通过药监系统取得准许证,海关凭准许证及常规申报文件放行。经营涉及管制清单的原料药或制剂的贸易企业,必须:

  • 核实每个产品是否含有目录内物质;
  • 确认是否适用”中国批准上市制剂”例外;
  • 在发货前取得相应准许证;
  • 在口岸按公布的参考编码如实准确申报。

2026年10月1日前应做的事

对医药进出口企业——包括向中国境内合同生产方供应原料药、或出口受管制成品的外国公司——实用核查清单如下:

  • 重新筛查产品组合。 将进出境管线中的每个品目与扩围后的药用类精神药品目录逐一比对,重点关注三个新增品种(中英文名称均需核对)。
  • 核实制剂例外。 目录增列不包含在中国境内批准上市的药品制剂。请确认你所运产品是否属于此类获批制剂,并在合规档案中留存注册证明文件。
  • 更新申报主数据。 若涉及管制物质,更新产品主数据、海关归类记录与参考商品编号,确保10月1日后的申报使用正确编码。
  • 核查准许证状态。 确认必要的进出口准许证已就位,并让内部或第三方申报人清楚理解药监准许证与海关放行之间的职责分工。
  • 备妥审计材料。 监管部门与海关可能核查申报货物与实际物质含量是否一致。留存检验报告、制剂配方单与供应链记录,以证明每批货物的真实状态。
  • 同步物流与外包伙伴。 若由第三方代理申报或负责跨境物流,应转发公告,使筛查更新贯穿整个链条,而不只停留在持证人一端。

给外国药企的实务提示

受影响最大的外国公司,是那些供应或采购上述三种新管制物质的企业,或在其药品中将此类物质作为中间体、杂质(超过适用阈值)出现的企业。值得注意:

  • 本公告属口岸申报便利化措施,本身并不改变准许证制度,管制物质仍须适用该制度。
  • “批准制剂”例外范围较窄:它保护在中国获批上市的药品制剂,不涵盖原料物质或未获批制剂。
  • 鉴于10月1日生效,凡9月下旬订舱、10月到港的货物,都应按新范围筛查,避免出现合规空档。

来源

  • 国家药品监督管理局 — 国家药监局 海关总署关于药用类精神药品进出口申报事项的公告(2026年第84号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902092356142.html
  • 中华人民共和国海关总署 — 政务公告列表(含2026年第84号、第128号、第129号等): http://www.customs.gov.cn/
  • 医药魔方 — 药用类精神药品进出口申报事项公告(品种与施行日期摘要): https://bydrug.pharmcube.com/news/detail/484ba2600ed6d80d29192ad8ba49dca8

相关阅读

  • 见:第九届进博会海关通关须知(370-ciie-2026-customs-clearance-guide)
  • 见:广东国际医疗服务试点与医药投资(329-guangdong-international-medical-services)